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Oxidative stress by excessively generated reactive oxygen species (ROS) is an 
important factor for cell and tissue damage. Environmental contaminants may 
generate ROS such as hydrogen peroxide, superoxide and hydroxyl radical. These 
active oxygen species if not neutralized by body's defence mechanism may react 
with biological macromolecules like DNA, proteins, fat etc. The ROS mediated 
damage to DNA may result in strand breaks, removal of nucleotides and 
modification of bases. 
Alachlor [2-chloro-(2,6-diethyl-N-methoxymethyl)acetamide] is a widely used 
chloroacetanilide herbicide to control annual grass and broadleaf weeds in the 
production of com, soybeans, peanuts etc; and has been classified as a probable 
human carcinogen. Therefore, its extensive use may be a threat (i) to the 
environment and (ii) among herbicide applicators. Ultimately, the human 
population may be at risk of developing disease(s). Alachlor is metabolized in liver 
and finally converted into 3,5-diethylbenzoquinone-4-imine pDEBQI] via the 
intermediates 2-chloro-N-(2,6-diethylphenyl)acetamide [CDEPA] and 2,6-
diethylaniline [DEA]. Alachlor and its metabolite, CDEPA, form covalent adduct 
with 2'-deoxyguanosine and 2'-deoxythymidine. Moreover, alachlor produces 
DNA single strand breaks via formation of DNA adduct and generation of fi'ee 
radicals. The formation of adduct may be an initial event in carcinogenesis. 
The present study involves modification of plasmid DNA (pUC18) with 
alachlor by incubating the reaction mixture for 72 hr at 37°C. The alachlor induced 
modifications in plasmid DNA have been studied by UV, fluorescence and 
CD spectroscopic techniques, HPLC analysis, restriction enzyme digestion. 
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nuclease SI sensitivity, agarose gel electrophoresis and thermal denaturation 
studies. 
The alachlor-modified plasmid DNA showed marked hyperchromicity at 260 
nm compared to plasmid DNA, indicating the generation of single strand breaks 
and destabilization of inter-base hydrogen-bonding. Furthermore, the decreased 
fluorescence intensity of alachlor-modified plasmid DNA and changes in CD 
spectrum are suggestive of alachlor induced structural perturbations in the 
macromolecule. 
In thermal denaturation studies, non-modified plasmid DNA did not show any 
melting in the temperature range of 35 °C-95 °C. Under identical experimental 
conditions, the Tm of alachlor(i50fiM)-modified plasmid DNA was found to be 
84 °C, whereas for alachlor(3oo/iM)-modified plasmid DNA the Tm was 89 °C. The 
melting of alachlor-modified plasmid DNA further substantiates structural changes 
in plasmid DNA brought about by alachlor. 
Formation of adduct between alachlor and DNA bases were probed by high-
performance liquid chromatography. Increased retention time for alachlor-treated 
guanine, compared to alachlor devoid guanine, revealed alachlor-guanine adduct 
formation. Alachlor-treated adenine and cytosine did not show any change in 
retention times compared to their corresponding controls. In case of thymine 
treated with alachlor, we noticed a kink without change in retention time. 
Single strand breaks in alachlor-modified plasmid DNA were detected by 
agarose gel electrophoresis in presence of nuclease SI enzyme. Alachlor 
modifications in plasmid DNA were also confirmed by restriction enzyme 
digestion. 
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The immunogenicity of alachlor(i50MM)-modified plasmid DNA, 
alachlor(3oonM)-modified plasmid DNA and plasmid DNA alone were probed by 
inducing antibodies in experimental animals. The repertoire of specificities of 
induced antibodies were evaluated by enzyme immunoassay. Alachlor(i50fiM)-
modified plasmid DNA was found to be highly immunogenic compared to its 
300|iM modified form. Plasmid DNA itself was a weak immunogen. 
In gel-shift assay, the retarded mobility of immunogen-antibody complex 
confirmed the antibody specificity. The induced antibodies exhibited 
polyspecificity showing cross-reactivity with alachlor-modified conformers of 
DNA and nitrogenous bases. 
Forty sera each of breast & lung, and 30 sera of thyroid cancer were subjected 
to binding studies with plasmid DNA and alachlor(i50nM)-modified plasmid DNA. 
Purified IgG from serum samples showing higher binding with alachlor-modified 
plasmid were subjected to competitive inhibition assay. Rest of the sera were 
discarded. The inhibition in breast cancer IgG with alachlor(i50nM)-modified 
plasmid DNA was in the range of 35-55%, whereas with control plasmid DNA 
inhibition was between 20-31%. The inhibifion in lung cancer IgG with 
alachlor(i50nM)-modified plasmid DNA was in the range of 37-48%, whereas with 
control plasmid DNA inhibition was in the range of 19-26%. Similarly, with 
thyroid cancer IgG the inhibition was between 35-55% when alachlor(i50jiM)-
modified plasmid DNA was used as inhibitor, whereas with plasmid DNA the 
inhibition was in the range of 18-31%. 
The results of this study conclusively point out that alachlor treatment causes 
structural perturbations in plasmid DNA making it immunogenic in comparison to 
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weak immunogenicity of control plasmid. Antibodies raised against alachlor-
modified plasmid DNA in rabbits exhibited polyspecificity with an array of 
antigens but its binding with epitopes on immunogen remained high. Furthermore, 
serum antibodies or IgG of breast, lung and thyroid cancer showed better binding 
with alachlor(i50nM)-modified plasmid DNA over control plasmid. Based on above 
findings, it is hypothesized that the poor metabolism of even the weak carcinogen 
may allow its persistence in the body and favor adduct formation with DNA. If not 
repaired, the carcinogen-DNA adduct may trigger carcinogenesis and induction of 
antibodies, simuhaneously or subsequently. 
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Oxidative stress by excessively generated reactive oxygen species (ROS) is an 
important factor for cell and tissue damage. Environmental contaminants may 
generate ROS such as hydrogen peroxide, superoxide and hydroxyl radical. These 
active oxygen species if not neutralized by body's defence mechanism may react 
with biological macromolecules like DNA, proteins, fat etc. The ROS mediated 
damage to DNA may result in strand breaks, removal of nucleotides and 
modification of bases. 
Alachlor [2-chloro-(2,6-diethyl-N-methoxymethyl)acetamide] is a widely used 
chloroacetanilide herbicide to control annual grass and broadleaf weeds in the 
production of com, soybeans, peanuts etc; and has been classified as a probable 
human carcinogen. Therefore, its extensive use may be a threat (i) to the 
environment and (ii) among herbicide applicators. Ultimately, the human 
population may be at risk of developing disease(s). Alachlor is metabolized in liver 
and finally converted into 3,5-diethylbenzoquinone-4-imine [DEBQI] via the 
intermediates 2-chloro-N-(2,6-diethylphenyl)acetamide [CDEPA] and 2,6-
diethylaniline [DEA]. Alachlor and its metabolite, CDEPA, form covalent adduct 
with 2'-deoxyguanosine and 2'-deoxythymidine. Moreover, alachlor produces 
DNA single strand breaks via formation of DNA adduct and generation of fi"ee 
radicals. The formation of adduct may be an initial event in carcinogenesis. 
The present study involves modification of plasmid DNA (pUC18) with 
alachlor by incubating the reaction mixture for 72 hr at 37°C. The alachlor induced 
modifications in plasmid DNA have been studied by UV, fluorescence and 
CD spectroscopic techniques, HPLC analysis, restriction enzyme digestion, 
nuclease SI sensitivity, agarose gel electrophoresis and thermal denaturation 
studies. 
The alachlor-modified plasmid DNA showed marked hyperchromicity at 
260 nm compared to plasmid DNA, indicating the generation of single strand 
breaks and destabilization of inter-base hydrogen-bonding. Furthermore, the 
decreased fluorescence intensity of alachlor-modified plasmid DNA and changes 
in CD spectrum are suggestive of alachlor induced structural perturbations in the 
macromolecule. 
In thermal denaturation studies, non-modified plasmid DNA did not show any 
melting in the temperature range of 35 °C-95 °C, Under identical experimental 
conditions, the Tm of aIachlor(l5o^M)-modified plasmid DNA was found to be 
84 °C, whereas for alachlor(3oonM)-modified plasmid DNA the Tm was 89 °C. The 
melting of alachlor-modified plasmid DNA further substantiates structural changes 
in plasmid DNA brought about by alachlor. 
Formation of adduct between alachlor and DNA bases were probed by high-
performance liquid chromatography. Increased retention time for alachlor-treated 
guanine, compared to alachlor devoid guanine, revealed alachlor-guanine adduct 
formation. Alachlor-treated adenine and cytosine did not show any change in 
retention times compared to their corresponding controls. In case of thymine 
treated with alachlor, we noticed a kink without change in retention time. 
Single strand breaks in alachlor-modified plasmid DNA were detected by 
agarose gel electrophoresis in presence of nuclease SI enzyme. Alachlor 
modifications in plasmid DNA were also confirmed by restriction enzyme 
digestion. 
The immunogenicity of alachlor(i50nM)-modified plasmid DNA, 
alachlor(3oo^M)-modified plasmid DNA and plasmid DNA alone were probed by 
inducing antibodies in experimental animals. The repertoire of specificities of 
induced antibodies were evaluated by enzyme immunoassay. Alachlor(i50nM)-
modified plasmid DNA was found to be highly immunogenic compared to its 
300(xM modified form. Plasmid DNA itself was a weak immunogen. 
In gel-shift assay, the retarded mobility of immunogen-antibody complex 
confirmed the antibody specificity. The induced antibodies exhibited 
polyspecificity showing cross-reactivity with alachlor-modified conformers of 
DNA and nitrogenous bases. 
Forty sera each of breast & lung, and 30 sera of thyroid cancer were subjected 
to binding studies with plasmid DNA and alachlor(i50nM)-modified plasmid DNA. 
Purified IgG from serum samples showing higher binding with alachlor-modified 
plasmid were subjected to competitive inhibition assay. Rest of the sera were 
discarded. The inhibition in breast cancer IgG with alachlor(i50iiM)-modified 
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plasmid DNA was in the range of 35-55%, whereas with control plasmid DNA 
inhibition was between 20-31%. The inhibition in lung cancer IgG with 
alachlor(i50nM)-modified plasmid DNA was in the range of 37-48%, whereas with 
control plasmid DNA inhibition was in the range of 19-26%. Similarly, with 
thyroid cancer IgG the inhibition was between 35-55%o when alachlor(i50nM)-
modified plasmid DNA was used as inhibitor, whereas with plasmid DNA the 
inhibition was in the range of 18-31%. 
The results of this study conclusively point out that alachlor treatment causes 
structural perturbations in plasmid DNA making it immunogenic in comparison to 
weak immunogenicity of control plasmid. Antibodies raised against alachlor-
modified plasmid DNA in rabbits exhibited polyspecificity with an array of 
antigens but its binding with epitopes on immunogen remained high. Furthermore, 
serum antibodies or IgG of breast, lung and thyroid cancer showed better binding 
with aIachlor(l5o^M)-modifled plasmid DNA over control plasmid. Based on above 
findings, it is hypothesized that the poor metabolism of even the weak carcinogen 
may allow its persistence in the body and favor adduct formation with DNA. If not 
repaired, the carcinogen-DNA adduct may trigger carcinogenesis and induction of 
antibodies, simultaneously or subsequently. 
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The right-handed helical structure proposed in the year 1953 by British 
Physicist turned Biologist Francis Crick and American Biochemist James 
D. Watson for deoxyribose nucleic acid known as DNA, heralded a revolution in 
understanding of biology at molecular level. For decades the B-forni was 
considered to be the only structure of DNA having biologic relevance, even though 
Rosalind Franklin's fiber diffraction data for A- and B-forms had clearly shown 
that the DNA molecule could readily undergo structural transitions (Franklin and 
Gosling, 1953). Depending upon the bio-environment, DNA molecule has 
enormous ability to undergo structufal changes by twisting, turning and stretching 
leading to pantheon of DNA structures such as A, B, C, D and V- forms (Bansal, 
1999). V-form of DNA is supercoiled that may contain regions of right-handed and 
left-handed DNA in pBR322 plasmid (Ban et al, 1996). B-DNA is most stable 
structure under physiological conditions represented by normal Watson-Crick base. 
The conformational stability (difference between the free energies of the folded 
and unfolded states) of DNA duplex is considered as a function of component 
energy terms, hydrophobicity, base stacking, hydrogen bonding. Van der Waals 
interactions and electrostatic parameters (Sundaralingam and Ponnuswamy, 2004). 
Thus, the different conformations adopted by DNA reflect its inherent enormous 
versatility. 
Essential features of plasmid DNA 
Plasmids are self-replicating DNA which are stably inherited in an 
extrachromosomal state. These are widely distributed throughout the prokaryotes, 
vary in size from less than IxlO^Daltons to greater than200xlO^Daltons. Plasmids 
encode only few proteins required for their own replication and in many cases 
encode only one of them. Plasmids exist in: - supercoiled, open circle and linear 
form. Purely linear plasmids have been reported in a variety of bacteria e.g. 
Streptomyces species and Borelia burgdorferri. They are transmitted from bacteria 
to bacteria by conjugation or transformation. 
Different variants of pBR322 have been constructed for the purpose of cloning. 
For example, pUC18 is a small, high copy number E. coli plasmid, 2.686 Kbp. 
pUC18 and pUC19 plasmids are identical except that they contain multiple cloning 
sites (MCS) arranged in opposite orientations. 
Antigenicity of native DNA 
For many years DNA was considered to be immunologically inert or inactive, 
but later antigenic properties of nucleic acids were found when DNA was 
identified to bind with lupus autoantibodies (Cepellini, 1957; Meischer and 
Strassie, 1957; Robbins et al, 1957). DNA is a complex macromolecule whose 
immunologic properties vary with base sequence and encompass both stimulation 
and inhibition (Messina et al, 1991; Krieg et al, 1995, 1998; Pisetsky, 1992, 
2000). 
ThI notion that DNA is immunologically inactive derives primarily from 
efforts to replicate systemic lupus by immunization of normal animals with native 
DNA. Mammalian DNA complexed with carriers such as histones, poly-L-lysine 
and methylated BSA elicited antibodies against single-stranded DNA (ssDNA) but 
fails to induce antibodies to double-stranded (dsDNA) (Stollar, 1975; Madaio 
et al, 1984). DNA complexed with 27 amino acid long nucleic acid binding 
peptide (Fus 1) induced antibodies against dsDNA (Desai and Marion, 2000). 
Studies on the antigenic specificity of anti-DNA antibodies have enforced the 
view that DNA is immunologically 'simple and bland'. Antibody reactivity to both 
forms of DNA suggested recognition of conserved conformational determinants 
(e.g. sugar-phosphate backbone of B-DNA) and lack of influence of DNA 
sequence microheterogeneity on antigenicity (Pisetsky, 1993). Immunization of 
experimental animals with synthetic nucleic acid polymers like poly(dT), poly(dC), 
poly(dl), poly(dG), left handed Z-DNA and synthetic forms of double-stranded 
DNA (dsDNA) barring of B-DNA can induce antibodies against the immunogen 
(Stollar, 1986). DNA modified with drugs, hormones, free radicals etc have 
elicited antibodies against the immunogen (Dixit et al, 2005; Habib et al, 2005; 
Khan et al, 2006). Polynucleotides in B-conformation acquired immunogenicity 
after modification with flirocoumarin (Arif and Ali, 1996). 
DNA may induce wide range of immune response depending upon its base 
sequence. Bacterial DNA, in contrast to mammalian DNA which is poorly 
immunogenic (Isenberg et al, 1994), induces both innate and adaptive immune 
response in normal healthy humans and animals (Wagner, 1999; Krieg, 2002; Zhu 
et al, 2003). Bacterial DNA induces antibodies in normal mice that are cross-
reactive with mammalian ssDNA. Immunization of NZB/NZW mice wiien 
immunized with either bacterial DNA or BK (human polyomavirus) viral DNA 
produced cross-reactive antibodies to mammalian double-stranded DNA (dsDNA) 
(Gilkeson et al, 1991; Fredriksen et al, 1994; Gilkeson et ai, 1995). Bacterial 
DNA functions like endotoxin and trigger innate immunity during infection (Wu 
et al., 1997). The immunostimulatory properties of bacterial DNA is because of the 
presence of short six-base motifs called CpG motifs or immunostimulatory 
sequences which distinguishes it from mammalian DNA. Bacterial DNA is 
mitogenic in mice and can stimulate B-cell activation and polyclonal antibody 
production whereas mammalian DNA has suppression potential and may prevent 
the expression of cytokines such as IL-12 and IFN-y (Messina et al., 1991; 
Tokunaga et ai, 1992; Halpern et al., 1996; Pisetsky, 1996). The immunological 
effects of nucleic acids can influence the pathogenesis of many infectious and 
autoimmune diseases. 
Antigenicity of plasmid DNA 
Immunization with naked plasmid DNA encoding foreign antigens induces 
cell-mediated and humoral immune response which provides protective immunity 
against numerous pathogens in a variety of animal species. Antigen presenting 
cells such as dendritic cells play a key role in the initiation of primary immune 
response after DNA vaccination (Babiuk et al., 2000; Nayak et al., 2006). 
Molecular basis of adjuvant effect of plasmid DNA was shown to be due to 
presence of unmethylated CpG motifs in certain base context (Sato et al., 1996; 
Krieg, 2000; Schneeberger et ai, 2004; Smolarczyk and Szala, 2004; Coban et al., 
2005). 
Bacterial DNA differs from mammalian DNA by the presence of unmethylated 
cytosine-phosphate-guanosine (CpG) motifs and these motifs cause potent 
activation of immune system. Bacterial DNA or oligonucleotides containing CpG 
motifs (CpG-ODN) cause B-cell proliferation, immunoglobulin secretion, 
activation of natural killer cells, lytic activity in cell and increased cytokine 
secretion (especially Thi cytokines such as IFN-y, TNF-a, IL-6, and IL-12). The 
activation capability is attributed to the series of CpG containing motifs that follow 
the formula 5'-purine purine CG pyrimidine pyrimidine-3' (Yi et al., 1996; 
Cowdery et al., 1996; Dallas et al., 1996; Krieg et ai, 1995, 2002; Klinman et al, 
1996, 2004; Comelie, 2004; Wattrang et al, 2005; Chen et al, 2006). Bacterial 
DNA can directly stimulate mitogenesis, antibody production and may serve as an 
adjuvant and function synergistically with other signals such as anti-Ig cells 
stimulated cell activation. Cytosine methylation or elimination of CpG from 
oligonucleotide abolished the lymphocyte stimulatory effect (Messina et al, 1991; 
Krieg et al, 1995; Yi et al, 1996). 
Plasmid vectors expressing large amount of gene product do not necessarily 
induce immune responses to encoded antigens but the immunogenicity of plasmid 
DNA requires short immunostimulatory sequences (ISS) that contain unmethylated 
CpG dinucleotide in context of certain flanking bases. These ISS include the 
following CpG containing hexamers: 5'-GACGTC-3', 5'-AGCGCT-3', and 
5'-AACGTT-3'. The ISS functions as immunolators and activate innate, humoral 
and cell mediated responses (Krieg, 1999; Klinman et al, 1999). Palindromic 
single-stranded immunostimulatory DNA sequences induce production of IFN-a, 
IFN-p and IFN-y from mouse splenocytes and human lymphocytes (Yamamoto 
etal,\991). 
Immunologic plasmid DNA can be divided into two distinct units. A 
transcription unit that directs antigen synthesis and an adjuvant unit in plasmid 
backbone that elicits the production of type-I IFN and IL-12 in transfected skin 
keratinocytes and antigen presenting cells (APCs) (Tighe et al, 1998). 
Keratinocytes and APCs transfected with ISS-containing plasmid DNA produces 
IFN-a and IL-12, which then induce Thi immune response against plasmid DNA-
encoded protein. Manipulation of plasmid DNA transcription unit to yield higher 
levels of antigen expression does not necessarily produce stronger immune 
response. Both the localization and the precise muhiple repeats of ISS within the 
plasmid backbone are important for DNA vaccination (Sato et al, 1996), 
DNA immunization technology is a very promising approach to the 
formulation of multivalent vaccines (Grifantini et al, 1998). DNA vaccines are 
new types of subunit vaccines allowing protein expression in mammalian cells 
after introduction of plasmid vectors encoding the selected protective antigen. 
Protective immunity conferred by DNA vaccines has been shown in many animal 
models against HIV, tuberculosis and cancer (Taracha et al., 2003; Lee ei ai, 
2004; Pavlenko et al, 2004). DNA vaccine research is providing new insights into 
some basic immunological mechanism of vaccination such as antigen presentation, 
role of effector cells and immunoregulatory factors (Mor and Eliza, 2001). 
Despite the remarkable results obtained with DNA vaccines in experimental 
animals, relatively little is known regarding the efficiency of DNA vaccination in 
humans. A more likely use for DNA vaccines is in preventing diseases for which 
there is significant morbidity and mortality associated with infection and where 
there is no vaccine or effective treatment is available:- such as drug-induced 
tuberculosis, hepatitis C, and HIV-1. DNA vaccines inducing cytotoxic 
T-lymphocyte responses play a role in control or elimination of tumors (Boyle 
etal, 1998). 
Pesticides 
Pesticides are ubiquitous contaminants of our environment and have been 
found in air, soil, water, human and animal tissues. A pesticide is defined as any 
substance or mixture of substances (i) intended for preventing, destroying or 
controlling any pest including vectors of human or animal diseases, unwanted 
species of plants or animals causing harm during the production, processing, 
storage, transport or marketing of food, and agricultural commodities, 
(ii) administered to animals for control of insects, or other pests in or on their 
bodies. (FAO, 1986). The term excludes fertilizers, plant and animal nutrients, 
food additives and animal drugs. 
Pesticide use is validated by its contributions to the society and by their nature. 
The introduction of new, more toxic and rapidly disseminating pesticides into the 
environment has necessitated accurate identification of their potential hazards to 
human health. Although pesticides can have deleterious effects but they have been 
a boon, especially to the developing nations to eradicate insect-borne endemic 
diseases to produce adequate food and to protect forests, plantations and fibers 
(Grover et al., 2003). At present there are more than thousand chemicals classified 
as pesticides and reports have shown that some of them have toxic properties. 
Pesticides are manufactured and released into the environment in large amounts 
(lARC, 1991). Exposure to pesticides may cause disorders of cardiovascular 
system, nervous system, sensory organs and respiratory system as well as reduced 
lung function (Podda et al., 1997). All populations have a degree of risk in relation 
to pesticide exposures from agricultural and non-agricultural use and through 
residues in food, workers exposed in pesticide production and farmers who use 
pesticides have higher risk of exposure and hence are more prone to pesticide 
heahh effects (Kiraly et al, 1979; Amr, 1999; Garaj-vrhovac and Zeljezic, 1999; 
Padmavathi et al., 2000). 
Pesticides with an extremely high acute toxicity may be easily metabolized and 
eliminated from the body. They may be less toxic and without carcinogenic and 
mutagenic properties. On the other hand, pesticides with low acute toxicity such as 
organo mercury compounds and some organochlorine compounds may accumulate 
in the body and cause chronic toxicity after long term exposure even in 
comparatively low doses (Dich et al, 1997). Chronic effects of pesticides include 
neurotoxicity, immunological effects, reproductive effects, developmental effects 
and carcinogenicity. Exposure to pesticides increases the risk of development of a 
neurodegenerative disease (Parkinson's disease) and certain types of cancers such 
as leukemia, testicular cancer, myeloma, Hodgkins and non-Hodgkins lymphoma. 
For example 2,4,5-trichlorophenoI causes soft tissue carcinoma while DDT, 
chlordecone, methoxychlor and mirex affect female reproductive system (Blair and 
Zahm, 1995; Alavanjae/a/., 1996; Rose era/., 1999). 
Pesticides and Immune system 
The immuno-regulatory network is able to recognize and neutralize potentially 
harmful agents. As a result, the organism remains resistant to infectious and 
malignant diseases. Chemical substances can cause alteration in immune system 
function leading to immunotoxicity (Luster, 1996). Several pesticides have marked 
effects on immune system. More potent of these are trichlorocyclohexadiene 
(TCCD), atrazine, captan, lead arsenate and triphenytin hydroxide. It is suspected 
that pesticides alter protein functions (e.g toluene diisocyanate) and may form 
hapten (Jakoby, 1980; Pan et al, 1989). Organochlorine pesticides such as DDT, 
hexachlorobenzene and pentachlorophenol dysregulate complement and alter the 
bactericidal, viricidal and phagocytic ability of neutrophils. They may also alter the 
receptor sites for hormones and transport enzymes resulting in damage to sodium 
pump (Olefir, 1974; Evdokimov, 1974; Reeves et ai, 1975; Rea, 1977). In contrast 
with immunosupression responses, exposure to some pesticides may result in 
increased immune responses, resulting in development of allergies and 
autoimmune diseases (Rose et al, 1999). 
Classification of pesticides 
Pesticides can be classified on the basis of (i) function, which includes insecticide, 
rodenticide and fungicide and (ii) chemical class, like organophosphates, 
organochlorines, S-triazines and pyrethroids. 
Insecticides include chlorinated hydrocarbons, organophosphates, carbamates and 
pyrethroids. 
(i) Organochlorines or chlorinated hydrocarbons 
Chlorinated hydrocarbons or chlorinated insecticides are lipid soluble, stored in 
fatty tissues and repeated small exposures may result in accumulation and toxicity. 
These are highly toxic to mammals. Many organochlorines such as DDT and 
dieldrin have been banned in United States. However lindane, endosulfan, 
methoxychlor and dicofol are still in use. Organochlorines are acutely toxic, 
potential carcinogens, reproductive toxicants and very persistent in the 
environment, 
(ii) Organophosphates 
These were the first insecticides used on a large scale to replace the chlorinated 
hydrocarbons. Unlike chlorinated hydrocarbons they are accumulated in the body 
tissues of humans or animals for a longer time. Organophosphate toxicity is the 
result of excessive stimulation of cholinergic nerves and the ability to inhibit acetyl 
cholinesterase. The symptoms of toxicity, as a result of cholinesterase inhibition, 
include headache, giddiness, nervousness, nausea, blurred vision, cyanosis, cardiac 
arrest and respiratory failure, 
(iii) Carbamates 
Carbamates are derivatives of carbamic acid. Carbamates like 
organophosphates are acetylcholine inhibitors. Carbamates do not accumulate in 
fatty tissues of animals. Carbamates act as contact insecticides. 
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(iv) Pyrethroids 
Pyrethroids function like organochlorines. They act as contact and stomach 
poison to insects. Pyrethroids include permethrin, cyalothrin, cypermethrin, 
bifenthrin, cyfluthrin, deltamethrin, fenvalerate. Pyrethroids have very short half-
life in the environment and are acutely toxic to humans. They mainly interact at the 
sodium channel by inhibiting the inactivation of the sodium current following 
membrane depolarization. Pyrethroids have the ability to (i) antagonize GABA 
mediated inhibition (ii) modulate nicotinic cholinergic transmission and 
(iii) enhance noradrenalin release. Chronic pyrethroid toxicity causes liver 
enlargement, accompanied by bile duct proliferation and focal necrosis of 
hepatocytes. 
Fungicides 
These are used to control molds and mildew. Skin and mucous membrane 
irritation are the adverse side effects of fungicides on human. Captan and maneb 
are classified as probable human carcinogen by USEPA. 
Herbicides 
Herbicides are used to control weeds in agriculture. Herbicides are generally 
less toxic than other pesticides but their excessive use combined with health related 
issues make it important to understand all aspects of chronic health effects related 
to these important chemicals. Herbicides can be classified according to the manner 
in which they are applied to plants or soil. Some commonly used herbicides are 
depicted in Table 1. 
On the basis of chemical structure herbicides are classified into: -
(i) Chlorophenoxy herbicides 
These include 2,4-dichlorophenoxyacetic acid and 2,4,5-trichloro-
phenoxyacetic acid characterized by the presence of simple acid esterified onto 
phenyl ring with one to three chlorine substitutions. They show less toxicity and 
the symptoms of poisoning include myotonia, anorexia, excessive thirst, tremors, 
ataxia, rapid breathing, paralysis and coma accompanied by death. Other signs of 
poisoning include neurological disorders, personality changes, sleep disturbance 
and impaired vision. 
(ii) Bipyridinium herbicides 
Bipyridyl means that the structure contains two pyridine rings in which one 
carbon atom is replaced by ethylene group. These include paraquat, diquat and 
difenzoquat. They are used as post-emergent herbicides and are the only herbicides 
containing quaternary nitrogen within the pyridyl rings. Bipyridinium herbicide 
toxicity involves the production of superoxides in response to cyclic oxidation-
reduction of the compound in tissues. Paraquat toxicity includes gastrointestinal 
tract irritation followed by liver, kidney and heart dysfunction, 
(iii) Triazines 
These consist of six membered ring with three nitrogen arranged symmetrically 
around the ring. These herbicides include atrazine, simazine, metribuzin, cyanazine 
and propazine. Triazine toxicity includes excitation followed by depression, 
reduced respiratory rates, motor in-coordination, spasms and hyperthermia, 
(iv) Chloroacetanilide herbicides 
Chloroacetanilide herbicides include alachlor, acetochlor, metolachlor and 
propanil. This class of herbicide is used primarily in the pre-emergence control of 
annual grass and broadleaf weeds in the production of corn, peanuts, soybeans etc. 
Their primary mechanism of action is not known but these are known to inhibit 
several metabolic processes including lipid biosynthesis and synthesis of proteins. 
Their half-life is 2-3 months and are not persistent in soil. The acute toxicity of 
chloroacetanilide herbicides is low with a lethal dose (LD50) of T4-2.0 g/kg body 
weight (Rose e/a/., 1999). 
Alachlor was first introduced by Monsanto Company in 1969 (USEPA, 1997), 
Alachlor belongs to the group of chloroacetanilide herbicides (Fig. 1). Alachlor 
[2-chloro-2,6-diethyl-N-(methoxymethyl)acetamide] is a pre-emergent and early 
post-emergent herbicide used mainly in the production of corn, soybeans, peanuts 
(Hayes and Laws, 1991; Genter et al, 2002). It is an ortho-disubstituted 
chloroacetanilide having structural similarity with propachlor, acetochlor, 
metolachlor and several other organochloride herbicides (Larsen and Bakke, 1981). 
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TABLE 1 
Some commonly used herbicides 
Triazines 
Chloroacetanilides 
Chlorophenoxy 
Atrazine, Cyanazine 
Alachlor, Metolachlor, Acetochlor, Propanil 
2,4-Dichlorophenoxyacetic acid, 2,4,5-
Trichlorophenoxyacetic acid 
Nitroanilines Trifluralin, Pendimethalin 
Phosphono amino acids Glyphosphate 
Thiocarbamates S-ethyl dipropyl carbamothioate (EPTC) 
Source: Rose etal., 1999. 
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CH2CH3 
ccx:H2a 
CH2OCH3 
CH2CH3 
Fig. 1. Structure of Alachlor [2-chloro-2,6-diethyl-N-(methoxymethyl) acetamide]. 
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AlachJor breaks down quickly in the soil by the action of bacteria, thereby 
increasing the level of degradative products of alachlor which exceed the level for 
alachlor itself Physical and chemical properties of alachlor are listed in Table 2. 
Alachlor and DNA damage 
A compound that directly or indirectly damages DNA is called as genotoxic 
compound. Earlier studies indicated that alachlor can induce DNA damage, 
mutagenicity and cytotoxicity (Plewa et ai, 1984; Lin el ai, 1987; Pinter et al., 
1989; Rabich et al, 1991). Alachlor-induced DNA single strand breaks have been 
reported in vivo in rat hepatocytes, brain tissue and human peripheral blood 
lymphocytes (Bonfanti et al, 1992; Bagchi et al, 1995; Ribas et al, 1995). 
Alachlor is an in vitro clastogen in Chinese hamster ovary cells and human blood 
lymphocytes (Georgian et al, 1983; Lin et al, 1987; Ribas et al, 1996). Alachlor 
have been demonstrated to be non-mutagenic with and without liver S9 activation 
in bacterial systems including Salmonella typhimurium. Bacillus subtilis and E.coli 
(Shirasue/a/., 1976, 1977; Probst e/a/., 1981; Eisenbeis e/a/., 1981; Plewa e/a/., 
1984; Pinter etal, 1989). Mutagenicity testing in eukaryotes showed alachlor to be 
genotoxic as such or in presence of various activation systems, Alachlor was found 
to be mutagenic in micronucleus test in the Drosophila wing spot test and in 
several plant systems (DeMarco et al, 1990; Torres et al, 1992; Aguirrezabalaga 
etal, 1994; Surrallese/a/., 1995), 
Alachlor and its metabolites 2-chloro-N-(2,6-diethylphenyl)acetamide 
[CDEPA] and 2,6-diethylaniline [DEA] form covalent derivatives with DNA and 
protein (Nelson and Ross, 1998). In the year 1995 Nesnow et al synthesized and 
characterized adduct of alachlor and CDEPA with 2'-deoxyguanosine, 
2'-deoxythymidine and their 3'-monophosphates. Alachlor and its metabolites 
covalently bind to the cysteinyl moieties of haemoglobin and plasma proteins 
forming adduct (Fig. 2), Acid degradation of alachlor-protein adduct yields 
3-(2',6'-diethylphenyl)-l,3-thiazolidine-4-one [TZO], which is known to be formed 
by all chloroacetanilides bound to proteins (Brown et al, 1988; Lambert, 1999), 
Reaction scheme of alachlor adducts with deoxyguanosine and deoxythymidine are 
depicted in Fig, 3, 
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TABLE 2 
Physical and chemical properties of Alachlor 
Chemical name 
Molecular formula 
Molecular weight 
Melting point 
Physical state 
Solubility 
Water solubility 
Stability 
Vapour pressure 
[2-chloro-2,6-diethyl-N-(methoxymethyl) 
acetamide] 
C,4H2(,C1N02 
269.8 
39.5 °C-41,5 °C 
Decomposition temperature 105 °C 
White or cream crystalline solid at room 
temperature 
Soluble in acetone, benzene, chloroform, ethanol, 
ether, dimethylsulphoxide and ethylacetate but 
sparingly soluble in heptane. 
Soluble in water (242 ppm at 25 °C) 
Hydrolysed by strong acids and alkali, stable to 
UV light. 
l,6xlO'^mmHgat25°C 
Source: Heydens, 1999. 
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3-(2, 6-diethylphenyl)-l,3-thiazoli(line-4-one [TZO] 
Fig. 2. Reaction scheme of alachlor adducts with protein cysteinyl sulfhydryl 
group. 
Source: Lambert e/a/., 1999. 
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Fig. 3. Reaction scheme of alachlor adducts with deoxyguanosine and 
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Source: Nesnow et al., 1995. 
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Literature records suggest that reactive oxygen species (ROS) are continuously 
generated from environmental contaminants such as herbicides, heavy metals and 
insecticides (Melchiorri el al, 1998; Risso-de Faverney e( al., 2001; Ledirace ctai, 
2005). Reactive oxygen species in supranormal levels can react with biological 
macromolecules, (DNA, proteins, lipids etc) resulting in oxidation and 
peroxidation (Pena-Llopis et al, 2003). ROS are the major source of DNA strand 
breaks, removal of nucleotides and modification of bases (Cooke et al., 2003). 
Moreover, the key metabolites of alachlor and acetochlor like quinone-imine can 
induce the formation of ROS (Meyskens et al., 2004; Toler, 2004). 
Cancer 
Cancer may be defined as a group of disease characterized by (i) an abnormal 
growth of cells (ii) ability to invade adjacent tissues and even distant organs and 
(iii) the eventual death of affected patient if the tumor has progressed beyond the 
stage when surgical intervention was possible. 
Malignant tumors are classified according to embryonic origin of the tissue 
fi'om which tumor is derived. Carcinomas arise fi"om endodermal or ectodermal 
tissues such as skin or the epithelial lining of internal organs and glands. Sarcomas 
arise from mesodermal connective tissues. Leukemias, myelomas and 
lymphomas originate from cells of bone marrow. Leukemias proliferate as single 
cells whereas lymphomas tend to grow as tumor masses. 
Cancer itself is a multistep process passing through the following stages:-
Initiation of cancer may involve changes in DNA. This could be in terms of an 
altered base or a miscoding lesion or rearrangements of segments of DNA, the 
activation and modulation of gene expression by neighbouring base sequences and 
gene duplication and activation of oncogenes (Cavenee and White, 1995). By 
selectively modifying gene expression in initiated cells, tumor promoters can elicit 
the production of clonally derived benign growth. These tumors can be converted 
into rapidly growing malignant neoplasms through further DNA damage (Guyton 
and Kensler, 1993). The initiated cells expand into nodules, papillomas or polyps, 
which can act as population for the ultimate development of cancer. 
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Promotion: The transformed cells remain harmless unless and until it is 
stimulated to undergo proliferation, upsetting cellular balance. In this phase, the 
initiated cell is exposed to tumor promoter (Upton et al., 1986) which causes cells 
to undergo proliferation. Promotion may be enhanced by the creation of a stimulus 
and a selective or differential inhibition of surrounding cells (Farber, 1984). 
Progression: Progression of cancer is the process through which successive 
changes in the neoplasm give rise to increasingly malignant sub-population 
involving mutation and chromosomal aberrations. Progression may be accelerated 
by repeated exposures to carcinogenic stimuli. Sensitivity to dietary compounds, 
inhibitors of growth and enhancers of differentiation gradually disappear until the 
tumor becomes progressively more autonomous. The cellular heterogeneity, a 
feature of malignant development, may be the consequence of early acquisition of 
gene-specific mutations that destabilize the genome e.g., mutation of p53 gene 
(Guyton and Kensler, 1993; Hartwell and Kastan, 1994; Fishel and Kolodner, 
1995). 
Cancer has multifactorial etiology, which includes both genetic and 
environmental factors (Gourley el al., 1992). There is a complex inter-relationship 
between hereditary susceptibility and environmental carcinogenic stimuli in the 
causation of a number of cancers. Environmental factors such as sunlight, 
radiations and pesticides are known to augment cancer (Ananthaswamy and 
Piercall, 1990; Liehr, 1997). High fat diet (Carroll et al., 1975), deep-fried food, 
high intake of red meat, low fiber diet and contaminants have been related to 
cancer. Consumption of tobacco which contains nitrosamine is the major cause for 
cancer of mouth, lung, larynx, pharynx and pancreas (WHO, 1983), Ionizing 
radiation is an established carcinogen. Furthermore, the excessive attack of ROS 
on DNA appears to be significant in the development of cancer (Frenkel, 1992; 
Leanderson, 1993; Feig e(al., 1994; Erhardt etal., 1997). 
Occupational exposure to xenobiotics may result in covalent binding to DNA, 
which leads to chromosome alterations and may be an initial event in 
carcinogenesis (Miller, 1978; Keith and Dirheimer, 1995), Long term pesticide 
exposure may result in increased incidence of some neoplastic diseases such as 
non-Hodgkin's lymphoma, soft tissue sarcoma, and mammary carcinoma (Hardell 
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and Sanstroem, 1979; Hardell and Eriksson, 1988; Alavanja el a/., 1990; Dich 
et al., 1997). Carcinogenic pesticides may increase the risk of cancer througli a 
variety of mechanisms including genotoxicity, tumor promotion, hormonal action 
and immunotoxicity (Selkirk and Soward, 1993). Some non-genotoxic pesticides 
have been evaluated as human carcinogens e.g. arsenic compounds. 
The formation of DNA adducts and single-strand breaks by genotoxic 
chemicals are a critical step in the initiation of cancer. US Environmental 
Protection Agency categorized alachlor as a probable human carcinogen (Blair 
et al., 1993). Alachlor is a proven carcinogen in laboratory animals but there is 
limited epidemiological information on cancer in alachlor-exposed population. 
Alachlor causes nasal, thyroid and stomach tumors in rats but not in mice (Thake 
et al., 1995; Heydens et al., 1999, 2000; Center et al., 2000). The mechanism of 
carcinogenicity of alachlor has not yet been elucidated but it has been proposed 
that alachlor forms a DNA-reactive metabolite called 3,5-diethylbenzoquinone-4-
imine [DEBQI]. 
Nasal tumors are produced as a result of species and tissue specific 
metabolism, nasal protein binding, cytotoxicity and cell proliferation (Heydens 
et al., 1999). Thyroid tumor follicles result from changes including the induction of 
hepatic uridine diphosphate glucoronyl transferase (UDPGT), increased thyroid 
hormone elimination and excessive TSH stimulation. This leads to hyperplasia and 
eventually neoplasia (Wilson et al., 1996; Acquavella et al., 2004). The proposed 
mode of action of alachlor is its metabolic conversion to quinone-imine through 
sulfoxide product, formation of protein adducts, generation of reactive oxygen 
radicals, modification of cell death, induction of sister chromatid exchange and 
compensatory hyperplasia leading to adenomas (Bagchi et al., 1995; Hill el al., 
1997; Lambert et al., 1999; Green et al., 2000; Center et al., 2000). Quinone-
imines arylate proteins undergo redox cycling and also have been implicated in 
acetaminophen-induced hepatoxicity and phenacetin-induced nasal carcinogenicity 
(Veronese et al., 1985; Porubek et al., 1987). 
Metabolism of alachlor 
Metabolism of alachlor is both species and tissue specific. The metabolism in 
rat liver microsomes is higher than mice and human. Alachlor metabolites have 
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been identified in monkey urine and in humans exposed to aJachlor. The marker of 
alachlor metaboHte in urine is 2,6-diethylaniline. Besides liver, alachlor is also 
metabolized in enterohepatic tissues such as rat olfactory tissues. Aryl amidase 
(a non-specific carboxylesterase) and aniline p-hydroxylase are involved in 
alachlor metabolism (Ttoh et al., 1980; Wirkner and Poelchen, 1996). Upon 
metabolism, alachlor changes to 2-chloro-N-(2,6-diethylphenyl)acetamide 
[CDEPA] & 2-chloro-N-(2(l-hydroxyethyl)-6-ethylphenyl)acetamide [CHEEPA]. 
Other metabolites of alachlor are alachlor-ethane sulfonic acid [alachlor-ESA], 
2-chloro-2,6-diethylacetamide [CDA] and 2-hydroxy-2,6-diethylacetanilide [HAD]. 
Moreover CDEPA is the most abundant metabolite of alachlor and acts as substrate 
for 2,6-diethylaniline [DEA] formation (Feng and Wratten, 1987; Feng et al., 
1990; Pereira and Rosted, 1990; Pereira et al, 1992; Pereira and Hostettler, 1993; 
Potter and Carpenter, 1995; Thurman et al., 1996). Alternatively, alachlor may be 
metabolized first in liver and these metabolites may be transported to target tissues 
such as nose. In target tissues metabolites get activated to reactive metabolites by 
appropriate enzyme (US, EPA, 1982; Cowell et al., 1987; Feng et al., 1990; 
Li etal., 1992). Mammalian metabolic fate of alachlor is given in Fig. 4. 
Alachlor is extensively metabolized through benzylic oxidation and glutathione 
(GSH) conjugation yielding glutathione conjugates, mercapturates and several 
oxidized metabolites (Sharp et al., 1981; Brown et al., 1988; Feng and Patanella, 
1988, 1989). Alachlor biotransformation in liver leads to the formation of 2-chloro-
N-(2,6-diethylphenyl)acetamide [CDEPA] by P-450 mono-oxygenase system, 
which is subsequently metabolized to 2,6-diethylaniline [DEA] through the 
microsomal arylamidase system as demonstrated in Fig. 5. The metabolic 
transformation of alachlor to DEA requires the cleavage of the arylamidase bond. 
This compound is further oxidized to 2,6-diethylnitrosobenzene [DENB], an 
unstable intermediate, or it is converted into 3,5-diethylbenzoquinone-4-imine 
[DEBQI], an electrophilic compound (Kimmel et al., 1986; Feng and Wratten, 
1987; Feng and Patanella, 1989; Feng et al., 1990). Glutathione plays a prominent 
role in alachlor metabolism through displacement of chloride and binding with 
quinine-imine metabolites. Alachlor and its metabolites are capable of reacting 
with cellular macromolecules (Brown et al., 1988). 
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Fig. 4. Metabolic activation pathway of alachlor in mammalian liver. 
Source: Coleman etal., 1999, 
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Fig. 5. Metabolic activation pathway of Alachlor in rodents. 
Source: Feng e/a/., 1990. 
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Alachlor as an environmental estrogen 
Estrogen (the female sex hormone) influences development, differentiation, 
and function of reproductive system (Enmark and Gustafsson, 1999). Estrogen 
receptors, namely Era and Erp mediate biological effect of estrogens and act as 
ligand-activated transcription factors that regulate expression of steroid genes 
(Nilsson etal, 2001; Levin, 2002). 
Various environmental contaminants exhibit their endocrine effects by 
mimicking endogenous hormones such as estrogen, altering the pattern of synthesis 
and metabolism of natural hormones and modifying hormone receptor levels 
(Colburn et al, 1993). Environmental estrogens represent a class of compounds 
that have been shown to mimic the effects and activity of naturally occurring 
ovarian hormone 17P-estradiol (Burow et al, 1999). 17p-estradiol plays an 
important role in survival of cells in various systems. Endogenous estrogens 
function as endocrine disruptors both in humans and wildlife leading to 
developmental defects and diseases including cancer (Colburn ei al., 1993; Wolff 
and Weston, 1997; Safe, 1998; Tyler et al, 1998; Miller and Sharpe, 1998; Barton 
and Andersen, 1998). Chemicals such as polychiorinated biphenyls (PCBs), 
dioxins, pesticides, phenols, alkylphenols, pthalates and parabens possess 
estrogenic properties and trigger mechanism of estrogenic activity (Miller and 
Sharpe, 1998; Andersen etal, 2002; Brody and Rudel, 2003). 
Various pesticides such as DDT, methoxychlor, toxaphen, dieldrin are 
estrogenic in nature (Wade et al, 1997; Bonefeld-jorgensen et al, 1997; Gray 
et al, 1999; Diel et al, 2002; Andersen et al, 2002; Scippo et al, 2003; Brody and 
Rudel, 2003), Alachlor has been reported to mimic estrogen which is capable of 
binding to the estrogenic receptor (ER) causing transcription in DNA and 
proliferation of MCF-7 cells in vitro (Soto etal, 1994, 1995; Klotz, 1996). 
Environmental estrogens act like endogenous estrogen and inhibit tumor 
necrosis factor alpha (TNF-a) induced apoptosis in ER-positive breast cancer cells 
(Burow et al, 1999), 17P-estradiol affects apoptosis through increased expression 
of Bcl-2, a member of family of apoptosis regulating protein. 
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Objective of the present study 
Alachlor is a chloroacetanilide herbicide and a potential human carcinogen 
widely used to control weeds in standing crops. Furthermore, alachlor and its 
metabolite(s) form adduct with DNA. 
In the present study, plasmid DNA (pUC18) was isolated from TBI strain of 
E.coli and subjected to alachlor modification in vitro. The structural alterations in 
DNA were studied by physico-chemical techniques like UV, fluorescence & 
circular dichroism spectroscopy, agarose gel electrophoresis, Nuclease SI 
digestibility, restriction enzyme digestion and HPLC. 
Polyclonal antibodies against plasmid DNA and alachlor-modified plasmid 
DNA were raised in experimental animals. The specificity of induced antibodies 
was evaluated by enzyme immunoassay and gel retardation assay. Immunoglobulin 
G isolated from sera of thyroid, lung, and breast cancer patients were subjected to 
competition ELISA using plasmid DNA and alachlor-modified plasmid DNA as 
antibody competitors. 
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MATERIALS 
Alachlor, nuclease SI, anti-human and anti-rabbit IgG alkaline phosphatase 
conjugate, methylated bovine serum albumin, bovine serum albumin, p-nitrophenyl 
phosphate, ethidium bromide, Coomassie Brilliant Blue G-250, sodium dodecyl 
sulphate, Tween-20, Freund's complete & incomplete adjuvants, agarose, sodium 
azide and dialysis tubing were purchased from Sigma Chemical Company, U.S.A 
100 bp DNA ladder plus was from MBI Fermentas. Plasmid isolation kit was from 
Qiagen, U.S.A. Protein A-Agarose and restriction enzymes were from Genei, 
India. Ficoll 400 and xylene cyanole FF were purchased from Pharmacia Fine 
Chemicals, Sweden. Luria broth was from Hi-Media Laboratories, India. Flat 
bottom ELISA plates (96 wells) were purchased from NUNC, Denmark. 
Acrylamide, bisacrylamide, ammonium persulphate and N,N,N',N'" 
tetramethylethylenediamine (TEMED) were from Bio-Rad Laboratories, U.S.A. 
Agar-Agar, EDTA (disodium salt), silver nitrate, dimethyl sulphoxide, formamide, 
chloroform, methanol, glacial acetic acid, iso-propanol, sodium chloride, sodium 
carbonate, sodium bicarbonate, magnesium chloride and potassium chloride were 
from Qualigens, India. Diphenylamine and ethanol were chemically pure. The 
remaining reagents/chemicals were of the highest analytical grade available. 
Equipments 
UV-visible Spectrophotometer (Shimadzu, UV-240) equipped with 
temperature-programmer and controller unit, Spectrofluorometer (Shimadzu, 
RF-5301), Spectropolarimeter (Jasco, J720), Multiskan ELISA microplate reader, 
RS-232C (Dynatech, U.S.A), ELICO pH meter (Ll-120), UV-transilluminator 
(Vilber Lourmat, France), Agarose gel electrophoresis assembly (Genei, India), 
Beckman's table top high speed cooling centrifuge (Avanti 30). Polyacrylamide 
gel electrophoresis assembly, HPLC Duo flow (Bio-Rad Laboratories, U.S.A) and 
CI8 column (Supelco discovery) were the major equipments used in this study. 
Collection of sera 
Blood samples of cancer patients were obtained from J.N. Medical College 
hospital of A.M.U., Aligarh, India and Sher-e-Kashmir Institute of Medical 
Sciences, Srinagar, India. The major diagnostic parameters for cancer cases were 
radiological imaging, laboratory tests and clinical investigation. Prior consent from 
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patients was obtained before withdrawing blood samples. Normal human sera were 
obtained from healthy humans. All samples were collected in a glass tube and 
allowed to clot for 30 min at 37°C and then centrifuged at 3000 rpm for 10 min. 
The sera were decomplemented by heating at 56 °C for 30 min and stored in 
aliquots at -20°C with 0.1 % sodium azide as preservative. 
METHODS 
Purification of calf thymus DNA 
Commercially available calf thymus DNA was purified free of proteins and 
single stranded regions (AH et al, 1985). DNA (2 mg/ml) was dissolved in 
O.lx SSC buffer (15 mM sodium citrate containing 150 mM sodium chloride, 
pH 7.3) and extracted with an equal volume of chloroform-isoamyl alcohol (24:1) 
by end-to-end mixing in a stoppered container. The aqueous layer containing DNA 
was separated from organic layer and re-extracted. The DNA was precipitated with 
two volumes of chilled absolute ethanol and collected on a glass rod. After drying 
in air, the DNA was dissolved in acetate buffer (30 mM sodium acetate containing 
30 mM zinc chloride, pH 5.0) and treated with nuclease SI (150 units/mg DNA) at 
37°C for 30 min to remove single stranded regions. The reaction was stopped by 
adding one-tenth volume of 200 mM EDTA (pH 8.0). Nuclease SI treated DNA 
was extracted twice with chloroform-isoamyl alcohol and finally precipitated with 
two volumes of chilled ethanol. The precipitate was dissolved in required buffer. 
Determination of DNA concentration 
DNA concentration was estimated colorimetrically by the method of Burton 
(1956) using diphenylamine reagent. This assay is based on color reaction of 
deoxyribose. Exposure of DNA to strong acids removes the purine bases, leaving a 
polymer known as apurinic acid. With the release of purine, the exposed reactive 
aldehyde group of deoxyribose reacts with diphenylamine producing blue color 
which serves as the basis for estimation of DNA concentration by Burton method. 
(a) Crystallization of diphenylamine 
Diphenylamine (2 g) was dissolved in 200 ml boiling hexane. After adding 
0.5 g of activated charcoal the hot mixture was filtered through Whatman filter 
paper (No. 1) and the filtrate was kept overnight at 4 °C. The preparation was 
finally dried at room temperature before use. 
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(b) Preparation of diphenylamine reagent 
To 750 mg of recrystallized diphenylamine was added 50 ml of glacial acetic 
acid followed by 0.75 ml concentrated sulphuric acid. The reagent was prepared 
fresh before use. 
(c) Procedure 
Varying amounts of DNA in 1.0 ml of assay volume was mixed with 1.0 ml of 
IN perchloric acid and incubated at 70°C for 15 min. One hundred microlitre of 
5.43 mM acetaldehyde was added followed by 2.0 ml of freshly prepared 
diphenylamine reagent. The contents were mixed and incubated at room 
temperature for 16-20 hr for color development. Absorbance was read at 600 nm 
and DNA concentration in unknown sample was determined from the standard plot 
of purified calf thymus DNA. 
Determination of Protein Concentration 
Protein was estimated by the methods of Lowry ei al. (1951) and Bradford 
(1976). 
Protein estimation by Folin's-Ciocalteu reagent (Lowry et aL method) 
Protein estimation by this method utilizes alkali (to keep the pH high), Cu^ *^  
ions (to chelate proteins) and tartarate (to keep the Cu^ ^ ions in solution at high 
pH). 
(a) Folin-Ciocalteu reagent 
The Folin-Ciocalteu reagent was diluted 1:4 with distilled water before use. 
(b) Alkaline copper reagent 
The components of alkaline copper reagent were prepared as follows: 
(i) Two percent sodium carbonate in 100 mM sodium hydroxide, 
(ii) 0.5 percent copper sulphate in 1.0 percent sodium-potassium tartarate. 
The working reagent was prepared fresh by mixing components (i) and (ii) in 
the ratio of 50:1. 
(c) Procedure 
Varying amounts of protein in 1.0 ml volume was mixed with 5.0 ml of freshly 
prepared alkaline copper reagent and incubated at room temperature for 10 min. 
One ml of working Folin-Ciocalteu reagent was added followed by 30 min 
incubation at room temperature. The absorbance was monitored at 660 nm. 
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The protein content of unknown sample was determined from the standard plot of 
bovine serum albumin. 
Protein estimation by dye-binding method (Bradford method) 
This assay is based on the change in absorption maximum of an acidic solution 
of Coomassie Brilliant Blue G-250 from 465 nm to 595 nm when protein binds to 
the dye. Both hydrophobic and ionic interactions stabilize the anionic form of the 
dye, causing a visible color change. 
(a) Dye preparation 
One hundred mg Coomassie Brilliant Blue G-250 was dissolved in 50 ml of 
95% ethanol and 100 ml of 85% (v/v) orthophosphoric acid was added. The 
resulting solution was diluted to a final volume of 1 litre and filtered through 
Whatman filter paper (No. 1) to remove undissolved particles. 
(b) Protein assay 
To one ml of solutions containing 10-100 |ig protein was added 5 ml of dye 
solution and contents were mixed by vortexing. The absorbance was read at 
595 nm after 5 min against a reagent blank. 
Preparation of bacterial culture and isolation of plasmid DNA (pUC18) 
(a) Materials used 
(i) Cell strain and media: TBI strain of E. coli was used to purify plasmid. Luria 
Bertani (LB) medium was used as growth medium and ampicillin was added at a 
concentration of 100 |ig/ml to the broth. 
(b) Buffers used 
Resuspension buffer (PI) 
50 mM Tris-HCl, pH 8.0; 10 mM EDTA; 100 ^g/ml RNase A 
Lysis buffer (P2) 
200 mM NaOH; 1% SDS (w/v) 
Neutralization buffer (P3) 
3.0 M potassium acetate, pH 5.5 
Equilibration buffer (QBT) 
750 mM NaCl; 50 mM MOPS, pH 7.0 
15% isopropanol (v/v); 0.15% Triton X-100 (v/v) 
28 
Wash buffer (QC) 
1.0 M NaCl; 50 mM MOPS, pH 7.0; 15% isopropanol (v/v) 
Elution buffer (QF) 
1.25 M NaCl; 50 mM Tris-Cl, pH 8.5; 15% isopropanol (v/v) 
TE buffer 
10 mM Tris-HCI, pH 8.0; 1 mM EDTA 
Plasmid DNA isolation 
E. coli cells containing plasmid were grown in 10 ml LB medium (starter 
culture) in presence of ampicillin (100 ng/ml). The above flask was subjected to 
vigorous shaking at 300 rpm for 8 hr at 37 °C. The culture was transferred to 500 
ml selective LB medium and incubated for 12 to 16 hr at 37 °C with vigorous 
shaking at 300 rpm. Bacterial cells were harvested by centrifugation at 6000 rpm 
for 15 min at 4 °C. The supernatant was discarded and centrifuge tubes were 
inverted to remove traces of supernatant. The bacterial pellet was resuspended in 
50 ml of PI buffer (containing RNase A) by vortexing. Fifty ml of P2 buffer was 
added to the suspension and contents were mixed gently end-to-end 5 to 6 times. 
After 5 min incubation at room temperature, 50 ml of chilled P3 buffer was added 
to the suspension and incubated for 30 min till fluffy white material was formed. 
The precipitated material contained genomic DNA, proteins, cell debris and traces 
of SDS. The contents were centrifliged at 11,000 rpm for 30 min at 4°C and pellet 
was discarded. Qiagen tip 2500 (ready to use column) was equilibrated by passing 
35 ml QBT buffer. Supernatant was applied to the tip and allowed to enter by 
gravity flow. Tip was washed with 200 ml QC buffer. Bound plasmid DNA was 
eluted with 35 ml elution buffer (QF). The plasmid DNA was precipitated by 
adding 24.5 ml of isopropanol at room temperature and precipitate was collected 
by centrifuging at 11,000 rpm for 30 min at 4 °C. The pellet was washed with 7 ml 
of 70% ethanoi and centrifliged at 11,000 rpm for 10 min. Supernatant was 
discarded carefully and pellet was air dried. The material was dissolved in minimal 
volume of TE buffer, pH 8.0. 
Modification of plasmid DNA (pUC18) by alachlor 
Plasmid DNA (pUC18) was modified with alachlor as described by (Nelson 
and Ross, 1998) with slight modification. Thirty \M of plasmid DNA was 
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thoroughly mixed with varying concentrations of alachlor (30 ^M, 150 [iM and 
300 ^M) in TE buffer (10 mM Tris-HCl containing 1 mM EDTA, pH 7.5) and 
incubated at 37 °C for 72 hr. At the end of 72 hr, the samples were extensively 
dialyzed against TE buffer to remove the unbound alachlor. 
Spectroscopic Analysis 
The ultraviolet absorption profile of plasmid DNA, alachlor and alachlor-
modified plasmid DNA were recorded in the wavelength range of 200-400 nm on 
spectrophotometer. 
Fluorescence emission profile of plasmid DNA and alachlor-modified plasmid 
DNA were recorded on spectrofluorometer in presence of ethidium bromide. 
Circular dichroism measurements 
Circular dichroism (CD) profile of plasmid DNA and alachlor-modified 
plasmid DNA were recorded on spectropolarimeter. The measurements were taken 
in 1 mm path length cells at 25 °C and the wavelength range was 220-350 nm. All 
scans were recorded at an interval of 0.2 nm. The base line was adjusted with PBS, 
pH 7.4 and the plasmid DNA was used at 0.03 mM concentration. Molar 
ellipticities [9] were calculated in terms of base pair concentration according to the 
following equation:-
[e] = — ^ — 
l O x c x d 
where, [0] is measured ellipticity in mdeg, 'c' is the molar concentrafion of 
plasmid DNA per base pair and 'd' is the path length. 
Heat induced melting of plasmid DNA and its modified counterpart 
Plasmid DNA and alachlor-modified plasmid DNA were subjected to thermal 
denaturation. The melting was monitored on Shimadzu UV-240 spectrophotometer 
coupled with temperature-programmer and controller assembly (Habib et al., 
2005). Samples were heated fi-om 30 °C to 95 °C at a rate of 1,5 °C/min after ten 
minute equilibration at 30 °C. The change in absorbance at 260 nm was recorded 
with increasing temperature. The transition temperature (Tm) was determined from 
percent denaturation data. 
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AT - A30 
Percent denaturation = x 100 
AF - A30 
Where, AT is the absorbance at a temperature T °C, AF is the final absorbance at 
95 °C and A30 is the initial absorbance at 30 °C. 
High-performance liquid chromatography 
High-performance liquid chromatography (HPLC) analysis of guanine, 
adenine, thymine & cytosine and their alachlor-treated forms were carried out on 
Biologic Duo Flow System equipped with UV-visible multiwavelength detector. 
The absorbance was monitored at 254 nm. Fifty microlitres of 50 ^M guanine, 
adenine, thymine or cytosine was loaded onto C-18 reversed phase column 
(Supelco Discovery, 25 cm X 4.6 mm; pore size, 5 p,M). The elution was carried 
out with 12.5 mM citric acid, 25 mM sodium acetate, 25 [M 
ethylenediaminetetraacetate (EDTA), pH 5.2 buffer at a flow rate of 1 ml/min. The 
formation of alachlor-base adduct was confirmed from changes in retention time 
compared to the retention time of their respective controls (Muldrew et al, 2002). 
Detection of strand breaks 
The strand breaks in modified plasmid DNA was ascertained by nuclease SI 
digestibility and agarose gel electrophoresis in presence of sodium hydroxide. 
(a) Nuclease SI digestibility 
SI nuclease (from Aspergillus oryzae) is a glycoprotein having a pFI 
optimum in the acidic range, used to probe structural transitions in DNA. It chops 
off single stranded DNA at 3'-phosphate phosphodiester bonds, releasing 
5'-phosphoryl mono- or oligonucleotides (Drew, 1984; Fowler and Skinner, 1986; 
Bemues et al., 1989). Nuclease SI can introduce breaks in double-stranded DNA, 
RNA and DNA/RNA hybrids but at high enzyme and at low salt concentrations 
(Vogt, 1973). 
Plasmid DNA and alachlor-modified plasmid DNA were characterized by 
nuclease SI digestibility (Matsuo and Ross, 1987). One |ig each of plasmid DNA 
and alachlor-modified plasmid DNA in acetate buffer (30 mM sodium acetate, 
1 mM zinc sulphate, 100 mM sodium chloride, pH 4.6) were treated with nuclease 
SI (1 unit/ng of DNA) for 30 min at 37°C. The reaction was stopped by adding 
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one-tenth volume of 200 mM EDTA, pH 8.0. The digested and control samples 
were subjected to agarose gel electrophoresis. 
One percent agarose powder in TAE buffer (40 mM Tris-acetate, pH 7.9 
containing 2 mM EDTA) was dissolved by heating. The solution was cooled to 
about 50 °C and then poured into gel tray (sealed from both sides) and allowed to 
solidify at room temperature. Plasmid DNA and alachlor-modified plasmid DNA 
treated with nuclease SI were mixed with one-tenth volume of sample buffer 
(0.125% bromophenol blue, 30% Ficoll 400, 500 mM EDTA in lOx 
electrophoresis buffer). The samples were loaded in the wells and electrophoresed 
for 2 hr at 25 mA current. The gel was stained with ethidium bromide (0.5 |ig/ml) 
and DNA was visualized under UV irradiation and photographed. 
(b) Agarose gel electrophoresis under alkaline conditions 
DNA single strand breaks were analyzed on agarose gel by the method of 
Freeman et al. (1986) and Chen et al. (1998). One |ig of plasmid DNA and 
alachlor-modified plasmid DNA were denatured at 100 °C for 3 min in presence of 
2.5 111 of (10 mM NaOH, 95% formamide, 0.05% bromophenol blue and 0.05% 
xylene cyanol). The treated samples were electrophoresed on 0.7% agarose gel 
containing 0.5 |ig/ml ethidium bromide in 40 mM Tris-borate buffer supplemented 
with 1 mM EDTA. The DNA was visualized under UV and photographed. 
Restriction digestion of plasmid DNA 
Plasmid DNA and alachlor-modified plasmid DNA were subjected to digestion 
by EcoRl (GAATTC), Pvul (CGATCG) and Smal (CCCGGG). One ^g of plasmid 
DNA or alachlor-modified plasmid DNA was digested with 2 units of above 
restriction enzymes in an assay volume of 40 fil at 37 °C for 3 hr. The reaction was 
stopped by adding one-tenth volume of sample buffer (0.125%) bromophenol blue, 
30%) Ficoll 400, 500 mM EDTA in lOx electrophoresis buffer). The samples 
digested with Pvul and Smal were electrophoresed on 1.5%) agarose gel for 4 hr at 
30 mA current while those digested with EcoRI were electrophoresed on 0.8% 
agarose gel for 2 hr at 25 mA. The gel was stained with ethidium bromide and 
visualized under UV light. 
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Immunization Schedule 
Rabbits weighing 1-1.5 Kg were separately immunized with alachlor(i50jiM)-
modified plasmid DNA, alachlor(3oonM)-modified plasmid DNA and plasmid DNA 
(50 \xg each). The immunogen was complexed with equal amount of methylated 
BSA and emulsified with an equal volume of Freund's complete adjuvant (first 
injection). Animals were injected intramuscularly, at multiple sites. Subsequent 
injections were given in Freund's incomplete adjuvant at weekly intervals with the 
same amount of immunogen. During the course of immunization each animal 
received 400 |ig antigen. Marginal ear vein of immunized animals was punctured 
and blood was carefully collected to prevent hemolysis. Pre-immune blood was 
collected prior to immunization. 
Isolation of IgG on Protein A-Agarose column 
Serum IgG was isolated by affinity chromatography on protein A-Agarose 
column. Serum (0.3 ml) diluted with equal volume of PBS, pH 7.4, was applied on 
top of the column equilibrated with PBS. The wash through was recycled 2-3 times 
and unbound material was removed by extensive washing with PBS. The bound 
IgG was eluted with 0.58% acetic acid in 0.85% sodium chloride (Goding, 1978) 
and was collected in a tube containing 1.0 ml of 1.0 M Tris-HCl, pH 8.5. l^ hree ml 
fractions were collected and read at 251 and 278 nm. The IgG concentration was 
determined considering 1.4 OD280 = 1.0 mg IgG/ml. The isolated IgG was dialyzed 
against PBS and stored at -20 °C with 0.1% sodium azide. 
SDS-Polyacrylamide gel electrophoresis 
The homogeneity of purified IgG was ascertained by polyacrylamide gel 
electrophoresis under non-reducing conditions (Laemmli, 1970). 
The following stock solutions were prepared: 
(a) Acrylamide-hisucrylanude (30:0.8) 
A stock solution was prepared by dissolving 30 gm of acrylamide and 0.8 gm 
of bisacrylamide in distilled water to a final volume of 100 ml. The solution was 
filtered and stored at 4 °C in an amber colored bottle. 
(b) Resolving gel buffer 
A stock solution was prepared by dissolving 36 gm Tris in 48 ml of 1.0 N HCl, 
pH adjusted to 8.8 and volume adjusted to 100 ml with distilled water. 
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(c) Electrode buffer 
3.03 gm Tris and 14.4 gm glycine were dissolved in distilled water, pH 
adjusted to 8.3 and 1.0 gm SDS. The volume was adjusted to one litre. 
Procedure of PAGE 
Glass plates separated by 1.5 mm thick spacer were sealed with 1% agarose 
from sides and bottom. The non-reducing gel was prepared, poured between the 
glass plates and allowed to polymerize at room temperature. 
Protein samples IgG were mixed with one-fourth volume of sample buffer 
(10% glycerol and 0.002% bromophenol blue in 10 times concentrated 0.5 M Tris-
HCI, pH 6.8) and were loaded into the wells. The electrophoresis was carried out at 
70 volts for 4 hr in Tris-glycine buffer. The gels were stained with silver nitrate. 
The staining process involved fixing the protein bands for 10 min in a mixture of 
40% methanol and 13.5% formaldehyde followed by twice washing with distilled 
v^ater at an interval of 5 min. Then the gel was immersed in 0.02%) sodium 
thiosulphate solution for 1 min followed by two wash with distilled water at an 
interval of 20 sec. The gel was finally immersed in 0.1%) silver nitrate solution for 
10 min and finally washed with distilled water. The gel was immersed in developer 
to facilitate staining. After appearance of bands the gel was treated with stopper 
solution. 
Protocol for preparing 7.5% resolving gel 
Components Volume 
Acrylamide - bisacrylamide 2.5 ml 
Resolving gel buffer 2.5 ml 
Distilled water 4.8 ml 
10% SDS 0.1ml 
1.5% ammonium persulphate 0.1 ml 
TEMED 6 ^ 1 
Total volume = 10 ml (approx) 
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Enzyme linked immunosorbent assay: Following reagents were prepared and 
used in ELISA: 
Tris buffered saline (TBS): 10 mM Tris, 150 mM NaCl, pH 7.4. 
Tris buffered saline containing Tween 20 (TBS-T): 20 mM Tris, 144 mM NaCl, 
2.68 mM KCl, pH 7.4 containing 500 )il Tween 20 per litre. 
Carbonate-bicarbonate buffer: 15 mM sodium carbonate, 35 mM sodium 
bicarbonate, pH 9.6 containing 2 mM magnesium chloride. 
Substrate: 500 |j,g p-nitophenyl phosphate per ml of carbonate-bicarbonate buffer, 
pH 9.6. 
Procedure 
ELISA was carried out on flat bottom polystyrene plates as described earlier 
(Ali and Alam, 2002). Briefly, microtitre wells were coated with one hundred 
microlitres of 2.5 |ig/ml of DNA antigen (in TBS, pH 7.4) and incubated for 2 hr at 
37 °C and overnight at 4 °C. Each sample was coated in duplicate and half of the 
plate served as control devoid of antigen only. The antigen-coated wells were 
emptied and washed thrice with TBS-T to remove unbound antigen. Unoccupied 
sites were blocked with 150 \i\ of 1.5% non-fat dry milk (in TBS, pH 7.4) for 
4-5 hr at 4 °C and then plates were washed once. In direct binding ELISA, 
antibodies were directly added into antigen coated wells and incubated for desired 
time period at 37°C and 4 °C respectively. The wells were emptied and extensively 
washed with TBS-T. Anti-immunoglobulin alkaline phosphatase conjugate (diluted 
as per manufacturer's instructions) was added to each well. The conjugate was 
incubated at 37 °C for 2 hr and then the plates were washed four times with TBS-T 
and three times with distilled water. Para-nitrophenyl phosphate was added and 
developed color was read at 410 nm in a microplate reader. The results were 
expressed as mean of difference of absorbance values in test and control wells 
(Atest ~ AcontroO-
Competition ELISA 
The antigenic specificity of antibodies was determined by competition ELISA. 
Varying amount of inhibitors (0-20 |ig/ml) were mixed with constant amount of 
antiserum or IgG. The mixture was incubated at room temperature for 2 hr and 
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overnight at 4 °C. The immune complex thus formed was coated in the wells 
instead of the serum. The remaining steps were the same as in direct binding 
ELISA. 
Percent inhibition was calculated using the formula; 
^inhibited 
Percent inhibition =1 — x 100 
•^uninhibited 
Gel-shift assay 
Antigen-antibody specificity was also confirmed by the gel retardation assay. A 
constant amount of DNA antigen (1 |ig) was mixed with varying amounts of IgG 
(Dixit and Ali, 2004; Waris and Alam, 2004) and the interaction was allowed for 
2 hr at 37 °C and overnight at 4 °C. At the end of incubation, one-tenth volume of 
sample buffer was added to antigen-antibody complex and electrophoresed on 1% 
agarose gel in TAE buffer (pH 7.9) for 2 hr at 30 mA current. The gels were 
stained with ethidium bromide (0.5 |ig/ml) and visualized under UV light and 
photographed. 
^msVLrs 
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Isolation of plasmid DNA 
Plasmid DNA (pUC18) was isolated from the culture lysate of E.coli (TBI strain) 
using plasmid purification kit. The UV absorption spectrum of isolated plasmid DNA 
gave characteristic Xmax at 260 nm (Fig. 6). The purity was adjudged from absorbance 
ratio (A260/A280) of 1.8 and electrophoresis in agarose gel. Different forms of isolated 
plasmid DNA are indicated in inset to Fig. 6. 
Modification of plasmid DNA by alachior 
Pilot experiments were carried out to select alachior concentration for 
modification of plasmid DNA. Various concentrations of alachior (30 jiM, 150 |iM 
and 300 |j.M) were thoroughly mixed with 30 |JM bp plasmid DNA and incubated for 
72 hr at 37 °C. At the end of incubation, excess alachior was removed by extensive 
dialysis against TE buffer (10 mM Tris-HCl, 1 mM Na2-EDTA pH 7.5). The alachior 
induced structural perturbations in plasmid DNA were studied by various techniques. 
Characterization of alachlor-modified plasmid DNA 
(i) Ultraviolet absorption spectroscopy 
Compared to plasmid DNA alone, its modification with different concentrations 
of alachior caused hyperchromicity at 260 nm (Fig. 7). The quantum of 
hyperchromicity went on decreasing with increase in alachior amount. Alachior did 
show absorbance but only in wavelength range of 200 nm to 300 nm. The ?w„ax for 
alachior was observed at 270 nm compared to 260 nm ^ max for plasmid DNA. 
(ii) Fluorescence spectroscopy 
Neither plasmid DNA nor alachior has its own fluorescence and therefore an 
extrinsic fluorophore, ethidium bromide, was utilized to look into the structure of 
plasmid DNA and its alachlor-modified forms. Plasmid DNA and its modified 
conformers were incubated with ethidium bromide for 30 min and emission profile 
were recorded using excitation wavelength of ethidium bromide (310 nm), and results 
are depicted in Fig. 8. Ethidium bromide gave an emission peak at around 585 nm. Its 
interaction with plasmid DNA caused enhancement in fluorescence intensity of 
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Fig. 6. UV absorption profile of isolated plasmid DNA. Inset: electrophoretic pattern 
of plasmid DNA (0.5 ^g) in 0.8% agarose gel. The electrophoresis was 
carried out for 2 hr at 30 mA current. 
38 
200 300 
WAVELENGTH(nm ) 
400 
Fig. 7. UV absorption profile of 30 fiM plasmid DNA ( ), and alachlor ( ). 
Plasmid DNA modified with 30 |JM alachlor ( ), 150 \M alachlor 
( ), and 300 i^M alachlor ( ). 
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Fig. 8. Emission profile of ethidium bromide ( ), ethidium bromide mixed v/ith 
plasmid DNA ( ), plasmid DNA with 150 |iM alachlor ( ), and plasmid 
DNA with 300 ^M alachlor ( ). 
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585 nm peak and birth of a new peak at 635 nm. The profile of plasmid DNA 
modified with 300 fiM alachlor was almost overlapping with control plasmid DNA 
spectrum except a slight decrease in fluorescence intensity at 585 nm peak. The 
pattern of plasmid DNA modified with 150 ^M alachlor was quite different. Firstly, 
the fluorescence intensity of 585 nm peak was significantly decreased, and secondly, 
the peak at 635 nm, which was prominent in plasmid DNA and its 300 i^M alachlor-
modified conformer, completely vanished and just a kink remained. The decrease in 
fluorescence intensities of modified conformers (especially plasmid DNA modified 
with 150 nM alachlor) as compared to plasmid DNA suggests alachlor-induced 
changes in plasmid DNA. 
(Hi) Circular dichroism (CD) spectroscopy 
The circular dichroism technique is used for elucidating conformation of a 
macromolecule, which measures differential absorption of right and left circularly 
polarized light. The CD spectra of nucleic acids result primarily from the spatial 
asymmetry of the constituent nucleotides. Under our experimental conditions, the CD 
spectrum of plasmid DNA (30 (iM bp) gave positive ellipticity in the wavelength 
range of 220-350 nm with a maximum at 260 nm (Fig. 9). Plasmid DNA modified 
with 150 \xM and 300 |JM alachlor showed ellipticity in the range of 220-350 nm but 
there was decrease in 260 nm positive ellipticity values to the extent of 23% and 13% 
respectively. This simply indicates that alachlor has produced perturbations in 
plasmid DNA without changing its overall conformation. 
(iv) Temperature induced melting of plasmid DNA and alachlor-modified 
plasmid DNA 
The structural changes in plasmid DNA by alachlor treatment were further 
characterized by measuring the progress of denaturation of alachlor-modified 
preparations at 260 nm as a function of temperature (Fig. 10). Melting behaviour of 
alachlor-modified plasmid DNA sample was monitored over a temperature range of 
30-95 °C at the rate of 1.5 °C/min and increase in absorbance at 260 nm was taken as 
a measure of melting. Under our experimental conditions, the isolated plasmid DNA 
did not show any melting in the temperature range of 30-95 °C and we did not subject 
it to mehing studies below 30 °C. Here, it would be pertinent to mention that in the 
studies on plasmid DNA carried out by Viglask et al. (2000), the author concluded 
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Fig. 9. Circular dichroic profile of 30 |iM plasmid DNA ( ), plasmid DNA with 
150 |iM alachlor ( ), and plasmid DNA with 300 \M alachlor ( ), 
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Fig. 10. Thermal melting profile of plasmid DNA modified with 150 |iM 
alachlor ( -0-) , and 300 \M alachlor ( - • - ) . 
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that the estimated melting temperature for plasmids with good supercoiled density 
are below physiological temperature. Plasmid DNA modified with 150 \iM alachlor 
showed early melting compared to alachlor(300nM)-modified conformer. The UV 
absorption and thermal denaturation characteristics of plasmid DNA and its alachlor-
modified forms are listed in Table 3. Results of this study speak of alachlor induced 
modification of plasmid DNA. Furthermore, the modification appears to have 
destroyed the superhelical density resulting in a linear structure. Comparison of data 
in Table 3 suggests enhanced modification of plasmid DNA by 150 \iM alachlor. 
(v) HPLC analysis of alachlor-treated bases 
Alachlor treated guanine, thymine, adenine and cytosine were individually 
subjected to high-performance liquid chromatography (HPLC) on CI8 column and the 
progress was monitored electrochemically at 254 nm. The samples were eluted 
isocratically at a flow rate of 1 ml/min. 
Under identical experimental conditions, guanine showed a retention time of 
-5.2 min (Fig. 11.1), whereas, the retention time for alachlor-treated guanine was 
observed at -7.0 min. Increased retention time for alachlor-treated guanine is 
suggestive of alachlor-guanine adduct formation. Both thymine and alachlor-treated 
thymine eluted at identical retention time of-5.0 min (Fig. 11.2). We observed a kink 
at -5.3 min in case of alachlor-treated thymine, which could be attributed to poor 
interaction of alachlor with thymine. The retention time for cytosine and its alachlor-
treated form was identical (Fig. 11.3). Adenine too did not show any change in the 
retention time upon treatment with alachlor (Fig. 11.4). 
(vi) Agarose gel electrophoresis 
The resolving power of agarose gels for topoisomers is excellent but more highly 
supercoiled species co-migrate as a broad band. Plasmid DNA and alachlor-modified 
plasmid DNA were subjected to electrophoresis in 0.8% agarose gel (Fig. 12). 
Plasmid DNA (lane 1) shows the usual electrophoretic pattern. Banding pattern of 
plasmid DNA treated with 30 [iM and 300 ^M (lane 2 & 4) showed the decrease in 
fluorescence intensities of supercoiled form and appearance of additional band due to 
nicks introduced in plasmid DNA by alachlor. The additional band did appear in 
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TABLE 3 
UV absorption and thermal denaturation characteristics of plasmid DNA 
and alachlor-modified plasmid DNA 
Parameter Plasmid Alachlor(i50nM)- Alachlor(3oonM)-
DNA modified plasmid modified plasmid 
DNA DNA 
Absorbance ratio (A260/A280) 18 1.6 1.7 
Onset of melting/C _ 71 78 
Melting temperature (Tm),°C _ 84 89 
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5.2 m i n. 
7 m i n. 
Retention time { min. ) 
Fig. 11.1 HPLC chromatogram of (a) guanine and (b) alachlor-lreated guanine. 
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Fig. 11.2 HPLC chromatogram of (a) thymine and (b) alachlor-treated thymine. 
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Fig. 11.3 HPLC chromatogram of (a) adenine and (b) alachlor-treated adenine. 
48 
0.00350-
0.00300-
0.00250-
3 0,00200-
"^  0.00150-
0.00100 -
0.00050-
0 . 0 -
la) 
.-r-
0.0 
5.2 min. 
2.0 ^.0 6.0 8.0 10.0 
O-OOiOO-
0.00350-
aoosoo-
0.00250-
0.00200-
0.00150-
0.00100-
0.00050-
0.0 
0.0 2.0 
5,2 min. 
4.0 5.0 8.0 10.0 
Reten t ion t ime (m in 
Fig. ] 1.4 HPLC chromatogram of (a) cytosine and (b) alachlor-treated cytosine. 
49 
1 2 3 4 
L 
.JH 
Fig. 12. Electrophoretic pattern of plasmid DNA (lanel). Lanes 2-4 show plasmid 
DNA treated with 30 |iM, 150 \iM, and 300 |iM alachlor. Electrophoresis was 
carried out on 0.8% agarose gel for 2 hr at 25 mA current. 
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150 ^M alachlor-modified plasmid DNA (lane 3) but the change in fluorescence 
intensity of supercoiled form was not electrophoretically identifiable in this case. 
(vli) Nuclease SI digestibility 
Nuclease SI was utilized to probe generation of any single strand breaks in 
plasmid DNA as a consequence of modification by alachlor. Plasmid DNA and its 
modified conformers were subjected to nuclease SI digestion (1 unit/)ig of DNA), 
Plasmid DNA (lane 1) treated with nuclease SI (lane 2) showed almost identical 
intensities in agarose gel (Fig. 13), thereby indicating that plasmid DNA preparation 
was free from nicks. The electrophoretic pattern of SI treated alachlor-modified forms 
(lanes 4 & 6) revealed partial digestion of supercoiled population and the left over 
appeared as a band of low fluorescence intensity compared to SI devoid modified 
forms (lanes 3 & 5). The above results indicate that alachlor modification of plasmid 
DNA does produce single strand breaks in plasmid DNA. 
The single strand breaks in the alachlor-modified plasmid DNA were ftirther 
analyzed in 0.7% agarose gel (Fig. 14). Plasmid DNA (lane 1) treated with NaOH 
(lane 2) showed almost same eletrophoretic pattern. Plasmid DNA modified with 150 
^M alachlor (lane 3) treated with NaOH (lane 4) revealed the appearance of band of 
low molecular weight, indicating the formation of single strands by the alachlor 
interaction. 
(vill) Restriction enzyme digestion of plasmid DNA and alachlor-modified 
plasmid DNA 
Plasmid DNA (pUC 18) and its 150 |iM alachlor-modified form were subjected to 
digestion with EcoRI, Pvul, and Smal. The above plasmid DNA has one recognition 
sequence each for EcoRl (GAATTC) and Smal (CCCGGG), and two for Pvul 
(CGATCG). The effect of these restriction enzymes was well pronounced in agarose 
gel (Fig. 15 «& 16). Alachlor-modified plasmid DNA treated with EcoRI (Fig. 15, lane 
4) showed almost no change in its electrophoretic pattern compared to alachlor-
modified plasmid DNA devoid of EcoRI (Fig. 15, lane 3). From the above, it may be 
interpreted that EcoRI recognition sequences in plasmid DNA have been modified by 
alachlor. Contrary to above the effect of Smal and Pvul on plasmid DNA or its 
alachlor-modified conformers were identical (Fig. 16) thereby indicating that 
restriction sites for Smal and Pvul on plasmid DNA were not affected by alachlor 
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Fig. 13. Nuclease SI digestibility of plasmid DNA (lane 1), plasmid DNA treated with 
SI nuclease (lane 2), DNA with 150 fiM alachlor (lane 3), DNA with 
150 nM alachlor treated with nuclease SI (lane 4), DNA with 300 i^M 
alachlor (lane 5), and DNA with 300 |iM alachlor treated with nuclease SI 
(lane 6). Electrophoresis was carried out on 0.8% agarose gel for 2 hr at 
25 mA current. 
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Fig. 14. Agarose gel electrophoretic pattern of plasmid DNA (lane 1), and NaOH 
treated plasmid DNA (lane 2). Lane 3 shows plasmid DNA modified with 150 
|iM alachlor and lane 4 depicts modified plasmid DNA treated with NaOH. 
Electrophoresis was carried out on 0.7% agarose gel for 90 min at 30 mA 
current. 
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Fig. 15. Banding pattern of plasmid DNA (lane 1) and 150 |iM alachlor-modified 
pasmid DNA (lane 3) in 0.8% agarose gel. Effect of EcoRI on plasmid DNA 
and its alachlor-modified conformer is shown in lanes 2 and 4 respectively. 
Electrophoresis was carried out for 2 hr at 25 mA current. 
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Fig. 16. Banding pattern of plasmid DNA and its 150 \iM alachlor-modified conformer 
in 1.5% agarose gel. Lanes 1 & 8 show resolution of 100 bp DNA ladder plus. 
Lane 2—> plasmid DNA; lane 3—> plasmid DNA treated with Pvul; and lane 
4-^ plasmid DNA treated with Smal. Lane—>^  5 shows alachlor(i50nM)-
modified plasmid DNA treated with Pvul (Lane 6) and Smal (Lane 7) 
respectively. Electrophoresis was carried out on 1.5% agarose gel for 4 hr at 
30 mA current. 
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treatment. Combined interpretations of Fig. 15 and 16 suggest m ^ ^cfilor binding 
(or modification) of plasmid DNA is most likely sequence specific. 
Immunogenicity of alachlor-modified plasmid DNA 
The immunogenicity of plasmid DNA and alachlor-modified plasmid DNA was 
evaluated by inducing antibodies in experimental animals. The antisera were 
characterized by enzyme immunoassays on solid phase. Antibody binding to 
immunogen was also characterized by gel retardation assay. 
Antibodies against alachlor-modified plasmid DNA 
The antisera obtained from immunized animals were subjected to direct binding 
immunoassay on polystyrene wells coated with immunogens (Fig. 17). The plasmid 
DNA modified with 150 [xM alachlor induced better antibody response compared to 
its 300 |iM counterpart. Preimmune sera used as control showed poor binding with 
immunogens. Plasmid DNA itself was not a good immunogen compared to alachlor-
modified conformers. The immunogen specificity of anti-alachlor(i50nM)-modified 
plasmid DNA antibodies was evaluated by inhibition assay (Fig. 18). A maximum of 
63% inhibition in antibody binding was observed at 20 ^g/ml of immunogen [alachlor 
(i5o^ M)-modified plasmid DNA]. Anti-alachlor(300fiM)-modified plasmid DNA 
antibodies were also subjected to inhibition ELISA using immunogen 
[alachlor(300|iM)-modified plasmid DNA] as antibody inhibitor (Fig. 19). In this case 
the antibody specificity for the immunogen was poor which is in consonance with 
direct binding ELISA resuU given in Fig. 17. Control plasmid DNA failed to trigger 
antibody response (Fig. 20). Further studies were carried out with alachlor(i50nM)-
modified plasmid DNA and antibodies raised against this neo-antigen. 
Purification and characterization of serum IgG 
Immunoglobulin G was isolated from sera by affinity chromatography on 
Protein A-Agarose column (Fig. 21). Protein A (from Staphylococcus aureus) 
binds to IgG from most mammalian species through unique histidine residues 
on Fc region of the molecule (Langone, 1978; Higgins et al., 1995). Purity of 
the isolated IgG (fraction no. 3) was ascertained by single band movement 
in SDS-polyacrylamide gel under non-reducing conditions (Fig. 21, inset). 
IgG isolated from preimmune serum and anti-alachlor(i50nM)-modified plasmid 
DNA serum was subjected to direct binding immunoassay on modules coated with 
56 
2.3 2.6 2.9 3.2 3.5 3.8 4.1 
LOG SERUM DILUTION 
Fig. 17. Direct binding ELISA of immune sera against plasraid DNA 
(—•—), alachlor(i50nM)-modified plasmid DNA (—A—), and alachlor 
(3ootiM)-modified plasmid DNA (—•—) binding to respective immunogen. The 
corresponding unfilled symbols (—•—, —A— —o—) indicate binding of 
preimmune sera. The microtitre wells were filled with 100 i^l of immunogen of 
interest (2.5 |ig/ml). 
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Fig. 18. Inhibition ELISA of preimmune (—A—) and immune serum against alachlor 
(i50nM)-modified plasmid DNA (—A—). The microtiter wells were filled with 
100 ii\ of alachlor(i50nM)-modified plasmid DNA (2.5 |.ig/ml). 
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Fig. 19. Inhibition ELISA of preimmune (—A—) and immune serum against 
alachlor(300nM)-modified plasmid DNA (—A—). The microtiter wells were 
filled with 100 |il of alachlor(300|aM)-modified plasmid DNA (2.5 ^g/ml). 
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INHIBITOR CONCENTRATION, \iglm\ 
Fig. 20. Inhibition ELISA of preimmune (—A—) and immune serum against plasmid 
DNA (—A—), The microtiter wells were filled with 100 |il of plasmid DNA 
(2.5 ^g/ml). 
60 
E 
c 
o 
00 
M 
I -
< 
LU 
O 
z 
< 
CO 
en 
o (0 
CD 
< 
Fig. 21. 
3 4 5 6 7 8 
FRACTION NUMBER 
10 
Fractionation of serum IgG through Protein A-Agarose column. Inset: 
SDS-PAGE of purified IgG (fraction no. 3) on 7.5% polyacrylamide gel. 
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plasmid DNA modified by 150 \iM alachlor. The anti-alach]or(i50MM)-modified 
plasmid DNA IgG showed strong binding with the coated antigen whereas 
preimmune IgG used as control showed negligible binding (Fig. 22 a & b). The 
specificity of anti-alachlor(i50MM)-modified plasmid DNA IgG was evaluated by 
competition ELISA. The specificity was evident from 74% inhibition in anti-
alach]or(i50fiM)-modified plasmid DNA IgG binding (Fig. 23). Fifty percent inhibition 
was observed at an inhibitor concentration of 9.2 )Lig/ml. Furthermore, plasmid DNA 
as a competitor showed nearly 25% inhibition in anti-alachlor(i50(jM)-modified 
plasmid DNA IgG binding. Comparison of data in Fig. 18 and Fig. 23 suggest that 
antigen-antibody interaction is more specific with purified IgG compared to whole 
serum. 
Cross-reactions of anti-alachlor(i50MM)-modified plasmid DNA IgG 
The cross-reactivity of anti-alachlor(i50nM)-modified plasmid DNA IgG was 
evaluated by competition ELISA with an array of antigens. Anti-aIachlor(i50nM)-
modified plasmid DNA IgG (30 ^g) incubated with varying concentration of calf 
thymus DNA and 400 bp calf thymus DNA showed 35% and 24%) inhibition in 
antibody binding, whereas their alachlor-modified conformers showed enhanced 
interaction with immune IgG (Fig. 24). Lymphocyte DNA of human origin modified 
by 150 [iM alachlor was found to be better recognized by anti-alachlor(i50(iM)-
modified plasmid DNA IgG compared to its non-modified form (Fig. 25). The 
binding specificity of anti-alachlor(i50(iM)-modified plasmid DNA IgG was also 
analyzed with DNA bases, alachlor-modified DNA bases, and ROS-modified DNA 
bases (Figs. 26-29). The DNA bases and their ROS counterpart showed moderate 
inhibition in anti-aIachlor(l50^M)-modified plasmid DNA IgG binding. The alachlor-
modified DNA bases were found to be effective inhibitors. Table 4 summarizes the 
results of cross-reaction studies of anti-alachlor(i50nM)-modified plasmid DNA IgG 
with an array of inhibitors. 
Gel-shift assay 
Antigen-antibody interaction was further evaluated by gel-shift assay. Constant 
amount of plasmid DNA or 150 jiM alachlor-modified plasmid DNA was incubated 
with varying amounts of anti-alachlor(i50nM)-modified plasmid DNA IgG for 2 hr 
at 37 °C and overnight at 4 °C. The antigen-antibody complex thus formed were then 
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Fig. 22. Direct binding ELISA of preimmune IgG (-A-) and anti-
alachlor(i50fiM)-modified plasmid DNA IgG ( - A - ) . The 
microliter wells were filled with 100 \i\ of plasmid DNA 
modified by 150 ^M alachlor (2.5 |ig/ml). 
(a) IgG amount was used in the range of 0-90 )ig/ml. 
(b) IgG amount was used in the range of 0-30 jig/ml. 
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Fig. 23. Inhibition of anti-alach]or(i50f4M)-modified plasmid DNA IgG binding to 
alachlor(i50nM)-modified plasmid DNA. The inhibitors were plasmid DNA 
(-A-), and aIachlor(i5o^M)-modified plasmid DNA ( -A- ) . The microliter 
wells were filled with 100 [i\ of alachlor(i5()nM)-modified plasmid DNA 
(2.5 ng/ml). 
64 
INHIBITOR CONCENTRATION, pg/ml 
Fig. 24. Inhibition of anti-alachlor(i50(iM)-modified plasmid DNA IgG binding by calf 
thymus DNA (-A-), alachlor(i50nM)-modified calf thymus DNA ( - A - ) , 400 
bp calf thymus DNA (-o-) , and alachlor(i50nM)-modified 400 bp calf thymus 
DNA ( - • - ) . The microtiter wells were filled with 100 |il of alachlor(i50fiM)-
modified plasmid DNA (2.5 |ig/ml). 
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INHIBITOR CONCENTRATION, pg/ml 
Fig. 25. Inhibition of anti-alach]or(]50MM)-modified plasmid DNA IgG binding by 
human lymphocyte DNA (-A-), and alachlor(i50nM)-modified lymphocyte 
DNA (-A-),The microtiter wells were filled with 100 |il of alachlor(i50tiM)-
modified plasmid DNA (2.5 |ig/ml). 
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INHIBITOR CONCENTRATION, \iglm\ 
Fig. 26. Inhibition of anti-aIachlor(i50nM)-modified plasmid DNA IgG binding by 
guanine (-A-), ROS-guanine ( -A- ) , and alachlor(i50jiM)-modified guanine 
( - • - ) , The microtiter wells were filled with 100 |LII of alachlor (isofiM)-
modified plasmid DNA (2.5 ng/ml). 
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INHIBITOR CONCENTRATION, Mg/ml 
Fig. 27. Inhibition of anti-alachlor(i50nM)-modified plasmid DNA IgG binding by 
adenine (-A-), ROS-modified adenine ( -A- ) , and aiachlor(i50nM)-modified 
adenine ( - • - ) . The microtiter wells were filled with 100 jil of 
alachlor(i50nM)-modified plasmid DNA (2.5 ng/ml). 
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INHIBITOR CONCENTRATION, \iglm\ 
Fig. 28. Inhibition of anti-alachlor(i5(VM)-modified plasmid DNA IgG binding by 
thymine (-A-), ROS-modified thymine ( -A- ) , and alachlor(i50nM)-
modifled thymine ( - • - ) . The microtiter wells were filled with 100 )il of 
alachlor(i50(iM)-modified plasmid DNA (2.5 pig/ml). 
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Fig. 29. Inhibition of anti-alachlor(i50MM)-modified plasmid DNA IgG binding by 
cytosine (-A-), ROS-modified cytosine ( -A- ) , and alachlor(i50nM)-
modified cytosine ( - • - ) . The microtiter wells were filled with 100 ^1 of 
alachlor(i5nfiM)-modified plasmid DNA (2.5 |ig/ml). 
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TABLE 4 
Cross-reactions of anti-alachIor(i5o^M)-modifiecl plasmid DNA IgG 
Inhibitor 
Alachlor(i50MM)-modified plasmid DNA 
Plasmid DNA 
Alachlor(i5QHM)-modified caif thymus DNA 
Calf thymus DNA 
Alachlor(i50(iM)-modified 400 bp calf thymus DNA 
400 bp calf thymus DNA 
Alachlor(i50nM)-modified human lymphocyte DNA 
Human lymphocyte DNA 
Alachlor(i50nM)-modified adenine 
ROS- modified adenine 
Adenine 
Alachlor(i50nM)-modified Guanine 
ROS-modified guanine 
Guanine 
Alachlor(i50MM)-modified thymine 
ROS-modified thymine 
Thymine 
Alachlor(i50nM)-modified cytosine 
ROS-modified cytosine 
Cytosine 
Maximum percent inhibition 
at 20 ng/ml 
74 
25 
66 
35 
68 
24 
57 
35 
30 
23 
30 
45 
20 
37 
36 
25 
22 
27 
19 
18 
The microtitre wells were filled with 100 \i\ of alachlor(i50nM)-modified plasmid 
DNA(2.5ng/ml). 
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electrophoresed for 2 hr at 30 mA and stained with ethidium bromide (Fig. 30 a, b). 
As shown in Fig. 30 a, the gradual increase in anti-alachlor(i50nM)-modified plasmid 
DNA IgG (lanes 2-5) has caused shift in the mobility of modified-plasmid DNA 
(lane 1) due to specific antigen-antibody interaction. Furthermore, under identical 
experimental conditions the unmodified plasmid DNA (Fig, 30, b) incubated with 
varying amounts of anti-alachlor(i50nM)-modified plasmid DNA IgG showed only a 
little shift in supercoiled form of plasmid at 100 ng of IgG (Lane 5). These results 
suggest that not all epitopes on plasmid DNA are polymerized into neoepitopes upon 
modification with alachlor. Thus the polyspecific anti-alachlor(i50nM)-modified 
plasmid DNA IgG is showing binding with plasmid DNA. 
Direct binding ELISA of cancer sera with plasmid DNA and 
alachlor(i5o,iM)-modified plasmid DNA 
In this study we analysed randomly selected 40 cases each of breast & lung cancer 
and 30 cases of thyroid cancer. Age- and sex-matched sera from normal healthy 
individuals served as control. All sera were diluted to 1; 100 in normal saline and were 
subjected to direct binding ELISA on solid phase separately coated with equal 
amounts of plasmid DNA and alachlor(l5o^M)-modifled plasmid DNA. Those cancer 
sera whose absorbance was less than or equal to control were discarded and not 
included in the results. Only 14 of 40 breast cancer sera showed higher binding with 
alachlor-modified plasmid DNA (Fig. 31). In case of lung cancer samples, only 12 
sera showed enhanced binding with modified plasmid DNA (Fig. 32). Direct binding 
ELISA data on 30 samples of thyroid cancer revealed that only 8 samples had better 
binding with modified-plasmid DNA (Fig. 33). 
Isolation of IgG from cancer sera 
IgG was isolated from selected sera of breast cancer (Fig. 31), lung cancer 
(Fig. 32), and thyroid cancer (Fig. 33) by passing through Protein A-Agarose column. 
The purity of the IgG isolated from all sera was confirmed by single movement in 
polyacrylamide gel. Fig, 34 shows the purity of IgG isolated from one normal serum, 
and one each from breast cancer, lung cancer, and thyroid cancer. 
Enzyme immunoassay of cancer IgG with plasmid DNA and alachlor (iso 
^M)-modified plasmid DNA 
IgG purified from breast cancer, lung cancer, and thyroid cancer sera were first 
subjected to direct binding ELISA on solid phase separately coated with plasmid 
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Fig. 30. Gel-shift assay of anti-alachIor(i50nM)-modified plasmid DNA IgG. 
(a) Alachlor(i50nM)-modified plasmid DNA (0.5 \xg, lane 1) was incubated with 
20, 50, 70, 100 \ig of anti-alachlor(i50nM)-modified plasmid DNA IgG (lanes 
2-5) and allowed to interact for 2 hr at 37 °C and overnight at 4 °C. 
(b) Plasmid DNA (0.5 \ig, lane 1) was incubated with 20, 50, 70 and 100 ^g of 
anti-alachlor(l5o^M)-modified plasmid DNA IgG (lanes 2-5) and 
incubated under identical conditions. 
Electrophoresis was performed on 1 % agarose gel for 2 hr at 30 mA current. 
73 
T — I — I — I — r 
10 11 12 13 14 
BREAST CANCER SERA 
Fig. 31. Direct binding ELISA of breast cancer serum samples (at 1:100 dilution) with 
plasmid DNA ( • ) and aIachIor(i5()nM)-modified piasmid DNA (0) . The 
microtiter wells were filled with 100 \i\ of respective antigens (2.5 |^ g/ml). 
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LUNG CANCER SERA 
Fig. 32. Direct binding ELISA of lung cancer scrum samples (at 1: 100 dilution) with 
plasmid DNA ( D ) and alachlor(i50^M)-modified plasmid DNA ( 0 ) . The 
microtiter wells were filled with 100 |il of respective antigens (2.5 jig/ml). 
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THYROID CANCER SERA 
Fig. 33. Direct binding ELISA of thyroid cancer serum samples (at 1: 100 dilution) with 
plasmid DNA ( D ) and alachlor(i50HM)-modified plasmid DNA (!»]). The 
microtiter wells were filled with 100 i^l of respective antigens (2.5 |.ig/ml) 
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Fig. 34. SDS-PAGE of IgG purified from normal human serum (lane 2), breast cancer 
serum no. 5 (lane 3), lung cancer serum no. 2 (lane 4) and thyroid cancer 
serum no. 4 (lane 5). Lanes 1 & 6 represents commercial preparation of BSA. 
Electrophoresis was carried out on 7.5% PAGE for 4 hr at 70 volts. 
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DNA and alachlor(i50)iM)-modified plasmid DNA to evaluaretl^ e^aqiOttfTt required for 
antigen saturation. The direct binding ELISA data of some of the breast cancer, 
thyroid cancer and lung cancer IgG are summarized in Table 5. 
The binding specificity of breast cancer IgG towards plasmid DNA and 
alachlor(i50MM)-modified plasmid DNA was evaluated by inhibition ELISA on solid 
phase. Breast cancer IgG was mixed with varying amounts of plasmid DNA and 
alachlor-modified plasmid DNA (0.1-20 |ng/ml) and incubated for 2 hr at 37 °C and 
overnight at 4 °C The resulting complex was coated instead of only serum/IgG. The 
remaining steps were same as for direct binding ELISA. The inhibitions results of 
breast cancer IgG are presented in Figs. 35-41. The inhibition in breast cancer IgG 
binding with alachlor(i50nM)-modified plasmid DNA varied from 35-55% while with 
control plasmid DNA the range was 20-31%. Inhibition data on 14 IgG samples of 
breast cancer are given in Table 6, 
The binding specificity of IgG isolated from 12 lung cancer sera towards plasmid 
DNA and alachlor(i50MM)-modified plasmid DNA was ascertained by inhibition 
ELISA. Fixed amount of lung cancer IgG were mixed to varying amounts of plasmid 
DNA and alachlor(i50jiM)-modified plasmid DNA (0.1-20 p^ g/ml) and incubated for 2 
hr at 37 °C and overnight at 4 °C and the plate was processed as described earlier. The 
inhibition results are presented in Figs. 42-47. The inhibition in lung cancer IgG 
binding with alachlor(]50MM)-modified plasmid DNA varied from 37-48%, whereas 
with control plasmid DNA the inhibition was in the range of 19-26%. 
Inhibition ELISA was also performed with IgG isolated from thyroid cancer sera. 
The immune complex was formed as described above and results are presented in 
Figs. 48-51. The inhibition data on lung and thyroid cancer IgG are summarized in 
Table 7 and 8 respectively. 
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TABLE 5 
Direct binding ELISA data of IgG isolated from breast, lung, and thyroid 
cancer sera 
Type of cancer/sera Concentration of IgG (|ig/ml) at which saturation 
No. of coated antigen was seen 
Breast 
1 50 
3 53 
5 51 
9 50 
12 55 
14 52 
Lung 
Thyroid 
1 52 
4 55 
5 56 
6 52 
12 58 
] 48 
4 45 
5 50 
8 52 
7<) 
INHIBITOR CONCENTRATION, pg/ml 
Fig. 35. Inhibition of breast cancer IgG 1 binding by plasmid DNA (-A-), 
alachlor(i50MM)-modified plasmid DNA ( -A- ) , and IgG 2 binding by 
plasmid DNA (-o-) , aiachlor(i50nM)-modified plasmid DNA ( - • - ) . The 
microtiter wells were filled with 100 ^1 of alachIor(i5()nM)-modiried plasmid 
DNA(2,5|LXg/ml). 
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Fig. 36. Inhibition of breast cancer IgG 3 binding by plasmid DNA (-A-), 
alachlor(i50nM)-modified plasmid DNA (-A-), and IgG 4 binding by 
plasmid DNA (-o-), alachlor(i50nM)-modified plasmid DNA (-•-). The 
microliter wells were filled with 100 \i\ of aIachlor(i50nM)-modifled plasmid 
DNA (2.5 i^g/ml). 
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Fig, 37, Inhibition of breast cancer IgG 5 binding by plasmid DNA (-A-), 
alachlor(i50(xM)-modified plasmid DNA ( -A- ) , and IgG 6 binding by 
plasmid DNA (-0-), alachlor(i50nM)-modified plasmid DNA ( - • - ) . The 
microtiter wells were filled with 100 pd of alachlor(i50jiM)-modified plasmid 
DNA(2.5)ag/ml). 
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INHIBITOR CONCENTRATION, |jg/ml 
Fig. 38. Inhibition of breast cancer IgG 7 binding by plasmid DNA (-A-), 
alachlor(i50nM)-modified plasmid DNA ( -A- ) , and IgG 8 binding by 
plasmid DNA (-0-) , alachlor(i50nM)-modified plasmid DNA ( - • - ) . The 
microtiter wells were filled with 100 |il of alachlor(i50M.M)-modified plasmid 
DNA(2.5^Ig/ml), 
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Fig. 39. Inhibition of breast cancer IgG 9 binding by plasmid DNA (-A-), 
aiachlor(i5()^M)-modified plasmid DNA ( -A- ) , and TgG 10 binding by 
plasmid DNA (-0-) , alachior(i50nM)-modified plasmid DNA ( - • - ) . The 
microliter wells were filled with 100 \i[ of alachlor(i50nM)-modified plasmid 
DNA (2.5 |ig/ml). 
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Fig. 40. Inhibition of breast cancer IgG 11 binding by plasmid DNA (-A-) , 
alachior(i50nM)-modified plasmid DNA ( - A - ) , and IgG 12 binding by 
plasmid DNA ( - 0 - ) , alachlor(i50nM)-modified plasmid DNA ( - • - ) . The 
microtiter wells were filled with 100 |^ 1 of aIachlor(i50jiM)-modified plasmid 
DNA (2.5 ^ig/ml). 
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INHIBITOR CONCENTRATION, ug/ml 
Fig. 41. Inhibition of breast cancer IgG 13 binding by plasmid DNA (-A-), 
aiachlor(i5o,.M)-modifled plasmid DNA ( -A- ) , and IgG 14 binding by 
plasmid DNA (-o-), alachlor(i50^M)-modified plasmid DNA ( - • - ) . The 
microtiter wells were filled with 100 pil of alachlor(i50nM)-modified plasmid 
DNA (2.5 ^g/ml). 
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TABLE 6 
rnhibition ELTSA data on breast cancer TgG 
Maximum percent inhibition at 20 pig/ml 
IgG 
Plasmid DNA Alachlor(l50^M)-modi^Ied 
plasmid DNA 
1 23 45 
2 25 38 
3 21 41 
4 23 36 
5 22 50 
6 29 42 
7 31 48 
8 26 35 
9 20 35 
10 22 49 
11 20 55 
12 24 36 
13 25 51 
14 23 45 
The microtiter wells were filled with 100 ^1 of alachlor(i50nM)-modified plasmid 
DNA(2.5|ig/ml). 
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Fig. 42. Inhibition of lung cancer IgG 1 binding by plasmid DNA (-A-) , 
alach]or(i50MM)-modified plasmid DNA ( - A - ) , and IgG 2 binding by plasmid 
DNA ( - 0 - ) , alachlor(i50nM)-modified plasmid DNA ( - • - ) . The microtiter 
wells were filled with 100 ^1 of alachlor(i50jiM)-modified plasmid DNA 
(2.5 ^ig/ml). 
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Fig. 43. Inhibition of lung cancer IgG 3 binding by plasmid DNA (-A-), 
alachlor(i50MM)-modified plasmid DNA ( -A- ) , and IgG 4 binding by plasmid 
DNA (-0-), alachlor(l5o^M)-modifled plasmid DNA ( - • - ) . The microtiter 
wells were filled with 100 ^I of alachlor(i50nM)-modified plasmid DNA 
(2.5^g/ml). 
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Fig. 44. Inhibition of lung cancer IgG 5 binding by plasmid DNA (-A-), 
alachIor(i5(vM)-modified plasmid DNA ( - A - ) , and IgG 6 binding by plasmid 
DNA ( - 0 - ) , alachlor(i50jiM)-modified plasmid DNA ( - • - ) . The microliter 
wells were filled with 100 \i\ of alachlor(i5o^M)-modified plasmid DNA 
(2.5 ^lg/ml). 
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Fig. 45. Inhibition of lung cancer IgG 7 binding by plasmid DNA (-A-), 
alachlor(i50nM)-modified plasmid DNA ( - A - ) , and IgG 8 binding by plasmid 
DNA ( - 0 - ) , aiachlor(i5()nM)-modified plasmid DNA ( - • - ) . The microtiter 
wells were filled with 100 |.il of alachlor(i50MM)-modified plasmid DNA 
(2.5 ^g/ml). 
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Fig. 46. Inhibition of lung cancer IgG 9 binding by plasmid DNA (-A-), 
aiachior(i50HM)-modified plasmid DNA (~A-), and IgG 10 binding by 
plasmid DNA (-0-), alachlor(i50nM)-modified plasmid DNA ( - • - ) . The 
microtiter wells were filled with 100 |il of aIachlor(i50nM)-modified plasmid 
DNA(2,5)ig/ml). 
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Fig. 47. Inhibition of lung cancer IgG 11 binding by plasmid DNA (-A-), 
aIachlor(i50MM)-modified plasmid DNA ( -A- ) , and IgG 12 binding by 
plasmid DNA (-o-) , aIachlor(i50(iM)-modified plasmid DNA ( - • - ) . The 
microtiter wells were filled with 100 [i\ of alachlor(i50nM)-modified plasmid 
DNA(2.5ug/ml). 
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Fig. 48. Inhibition of thyroid cancer IgG 1 binding by plasmid DNA (-A-), 
aIachlor(i50nM)-modified plasmid DNA ( -A- ) , and IgG 2 binding by plasmid 
DNA (-0-), alachlor(i50nM)-modified plasmid DNA ( - • - ) . The microliter 
wells were filled with 100 (.il of alachior(i50nM)-modified plasmid DNA 
(2.5 ^ig/ml). 
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Fig. 49. Inhibition of thyroid cancer IgG 3 binding by plasmid DNA (-A-), 
alachlor(i50MM)-modified plasmid DNA ( -A- ) , and IgG 4 binding by plasmid 
DNA (-0-), alachlor(i50nM)-modified plasmid DNA ( - • - ) . The microliter 
wells were filled with 100 }il of alachlor(i50,j.M)-modified plasmid DNA 
(2.5 ^ig/ml). 
95 
z 
o H 
ffl 
I 
Z 
H 
Z 
Ui 
O 
Q: 
UJ 
0. 
zo 
50 
75 
100 I— -r 1 - I "I -I——1——I—T-T—r-r~r~i -T T—TI I 
0.1 1 10 
INHIBITOR CONCENTRATION, pg/ml 
100 
Fig. 50. Inhibition of thyroid cancer IgG 5 binding by plasmid DNA (-A-), 
aIachIor(i50nM)-modified plasmid DNA ( -A- ) , and IgG 6 binding by 
plasmid DNA (-0-), alachlor(i50MM)-modified plasmid DNA ( - • - ) . The 
microtiter wells were filled with 100 |il of alachlor(i50M.M)-modified plasmid 
DNA (2.5 ^g/ml). 
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Fig. 51. Inhibition of thyroid cancer IgG 7 binding by plasmid DNA (-A-), 
a]achlor(i5o^M)-modified plasmid DNA ( -A-) , and IgG 8 binding by plasmid 
DNA (-0-), alachior(i5()(iM)-modified plasmid DNA ( - • - ) . The microtiter 
wells were filled with 100 \i\ of alachior(i50pM)-modified plasmid DNA 
(2.5 ^g/ml). 
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TABLE 7 
Inhibition ELISA data on lung cancer 
IgG 
Maximum percent inhibition at 20 |ig/ml 
Plasmid DNA 
23 
25 
22 
25 
25 
26 
22 
20 
22 
19 
23 
25 
AIachlor(i50nivi)-modified 
plasmid DNA 
45 
38 
47 
48 
46 
37 
47 
41 
42 
39 
44 
45 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
The microtiter wells were filled with 100 [i\ of alachlor(i50nM)-modified plasmid 
DNA (2.5 /ig/ml). 
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TABLE 8 
Inhibition ELISA data on thyroid cancer 
IgG 
Maximum percent inhibition at 20 [ig/m\ 
Plasmid DNA 
22 
25 
29 
31 
18 
20 
19 
24 
Alachlor(i50nM)-modified 
plasmid DNA 
35 
42 
50 
55 
35 
53 
38 
41 
2 
3 
4 
5 
6 
7 
8 
The microtiter wells were filled with 100 |LI1 of alachlor(i50nM)-modified plasmid 
DNA (2.5 ng/ml). 
(DISCVSSIO^K 
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Chemical carcinogens require activation to reactive intermediates that bind to 
nucleophilic centres in nucleic acids thereby forming covalent adducts. DNA-adduct 
formation with chemical carcinogen (i.e. covalent modification of DNA) is a 
biomarker for elucidating the epidemiology of cancer (Wogan, 1989; Poirier and 
Beland, 1992). Adduct levels reflect variables that comprise extent and frequency of 
chemical exposure, xenobiotic metabolism, rate of covalent binding of metabolites to 
DNA and rate of adduct repair (Harris, 1991; Poirier and Beland, 1992). DNA adducts 
such as 7-methy!guanine, 8-oxoguanine, thymine glycol etc., have been detected in 
humans by combination of methods such as primary purification, detection and use of 
standards (Hemminki ei al., 1995). Competitive DNA repair assay has been used to 
measure 7-methylguanine in human DNA (Souliotis et al., 1990). Treatment of DNA 
with 8-methoxypsoralen (a drug used in the treatment of psoriasis) forms covalent 
adduct which is highly immunogenic (Arif and Ali, 1996). Besides inducing 
carcinogenesis, the carcinogen-DNA adducts may also become immunologically 
active that may elicit antibody response. Antibodies elicited against DNA-adduct have 
been used to quantify and localize xenobiotic-induced DNA damage. 
Occupational exposure to xenobiotics may result in covalent binding of DNA 
which may cause chromosome alteration (IARC, 1991; Fairbairn et al., 1995). 
AJachlor [2-chloro-(2,6-diethyI-N-methoxymethyl)acetamide] is a pre- and early post-
emergent chloroacetanilide herbicide widely used for the control of annual grasses 
and broadleaf weeds in crops like com, soybeans, peanuts etc. (Hayes and Laws, 
1991). Alachlor is metabolized through network of metabolic pathways in both 
hepatic and extrahepatic tissues of rodents and mammals by cytochrome P-450 mono-
oxygenase system (Coleman et al., 1999). Both arylamidase (a non-specific 
carboxylesterase) and aniline p-hydroxylase are involved in alachlor metabolism (Itoh 
et al., 1980; Wirkner and Poelchen, 1996). In humans CYP 3A4 isoform is the most 
abundantly expressed and is responsible for metabolism of alachlor to 2-chloro-N-
(2,6-diethylphenyl)acetamide [CDEPA] (Li et al., 1995). Alachlor metabolism 
involves formation of [CDEPA] and 2,6-diethylaniline [DEA], which on further 
oxidation yields an unstable intermediate, 3,5-diethylbenzoquinone-4-imine [DEBQI], 
capable of binding to macromolecules. 
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Herbicides, insecticides and heavy metals continuously generate reactive oxygen 
species (ROS) which in supranormal level can oxidize proteins, cause lipid 
peroxidation and DNA damage (Pena-Llopis et al., 2003). Structurally unrelated 
xenobiotics (alachlor, paraquat, CCI4 etc) induce oxidative stress, thereby enhance the 
urinary excretion of malondialdehyde, formaldehyde, acetaldehyde and acetone 
(Stohs, 1990; Numane/a/., 1990; Shara eial., 1992). 
Alachlor causes DNA single strand breaks (Bonfanti et al, 1992), induces 
chromosomal aberrations, sister chromatid exchange and micronuclei in mammalian 
cells (Georgian et al., 1983; Lin et al., 1987; Meisner et al., 1992). Literature records 
suggest that alachlor-induced DNA damage is mediated by (i) adduct formation 
through the DNA reactive metabolite DEBQI and (ii) generation of reactive oxygen 
species (Akubue and Stohs, 1993; Hill et al, 1997). 
In the present study, plasmid DNA (pUC18) was modified by alachor. The 
alachlor modification of plasmid DNA produced hyperchromic effect. Treatment of 
plasmid DNA with 30 i^M, 150 pM and 300 \M alachlor exhibited 46.6%, 34.42% 
and 11.11% hyperchromicity respectively. The observed hyperchromicity 
(irrespective of quantum) appears to be the consequence of single strand breaks, 
loosening of stacked bases, and destabilization of hydrogen bonds. 
The fluorescence studies of alachlor(i50nM)-modified plasmid DNA in presence of 
ethidium bromide revealed decrease in fluorescence intensity at 585 nm and birth of a 
new peak at 635 nm as compared to control plasmid DNA. The decrease in 
fluorescence intensity of alachlor-treated plasmid DNA indicates perturbations in the 
structural integrity of plasmid DNA which might decrease the binding of ethidium 
bromide. 
The circular dichroic profile of DNA is due to base stacking and helicity of DNA. 
The circular dichroic studies of alachior(i50(iM)-modified plasmid DNA showed 9.25% 
decrease in ellipticity, whereas its 300 \M modified analog showed 5.55% decrease 
compared to control plasmid DNA. The decrease in ellipticity could be due to the 
unstacking of bases, thereby resulting in helix destabilization. 
Stacking of bases and hydrogen bonding stabilize DNA structure and their 
disruption causes denaturation (Thomas, 1993). Earlier report on plasmid DNA 
melting concluded that plasmids with good supercoiled density melt below 
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physiological temperature (Viglask et ai, 2000). In this context, we would like to 
mention that our control plasmid DNA also did not show melting in the temperature 
range of 30-95 °C. In other words, it may be said that the isolated plasmid DNA has 
good supercoiled density. Alachlor(i50MM)-modified plasmid DNA began to melt at 
71 °C onwards and Tm was calculated to be 84 °C, while 300 [iM alachlor-modified 
plasmid DNA started melting at 78 °C and the Tm was found to be 89 °C. The results 
suggest that 150 \iM alachlor is more effective in modifying plasmid DNA structure. 
Furthermore, it indicates that the treatment of plasmid DNA with alachlor disrupted 
the plasmid DNA structure rendering it susceptible to heat denaturation. 
In our studies alachlor-induced single strand breaks in plasmid DNA was detected 
in agarose gel. The electrophoretic pattern of 30 pM- and 300 jjM alachlor-treated 
plasmid DNA revealed the decrease in fluorescence intensity of supercoiled form and 
appearance of some new bands. The banding pattern of 150 |j.M alachlor-modified 
plasmid DNA was almost similar to 30 .^M and 300 fiM forms but no visible decrease 
in fluorescence intensity of supercoiled band was seen. 
DNA damaged by various agents (e.g. free radicals, UV light, hormones) may act 
as substrate for nuclease SI (Kato and Fraser, 1973; Slor and Lev, 1973; Shishido and 
Ando, 1974; Yamasaki et ai, 1977). Nuclease SI is a single strand DNA specific 
enzyme used to probe alteration in DNA structure. Alachlor-induced single strand 
breaks in plasmid DNA were studied by nuclease SI digestibility. There was partial 
digestion of supercoiled form of alachlor-modified plasmid DNA compared to control 
plasmid DNA which remained undigested. The nuclease SI sensitivity to alachlor-
modified plasmid DNA might be the result of nicks introduced by alachlor. This may 
produce looseness in normal stacking of bases which may propagate to alter hydrogen 
bonding and finally generation of some single strands. 
The single strand breaks in alachlor(l5o^M)-modifled plasmid DNA were ftjrther 
confirmed by alkali treatment of plasmid DNA and alachlor(i50nM)-modified plasmid 
DNA. The banding pattern of plasmid DNA and alkali treated plasmid DNA was 
identical. However, alkali treated alachlor(i50nM)-modified plasmid DNA showed 
additional band of low molecular weight. The result reiterates the presence of nicks on 
alachlor-modified plasmid DNA. 
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Plasmid DNA and alach]or(i50fiM)-modified plasmid DNA were treated with EcoRI, 
Smal and Pvul restriction enzymes. Treatment of plasmid DNA with above enzymes 
confirmed the presence of restriction sites. Treatment of alachlor(i50nM)-modified 
plasmid DNA with EcoRI resulted in the loss of EcoRI restriction site compared to 
control plasmid DNA. This indicates that alachlor has modified the EcoRI restriction 
site. The electrophoretic pattern of plasmid DNA and alachlor(i50nM)-modified 
plasmid DNA were identical when treated with Pvul and Smal restriction enzymes. 
This clearly suggests that Pvul and Smal restriction sites are intact. Furthermore, 
alachlor binding to pUCl 8 genome appears to be sequence specific. 
DNA adducts are covalently modified bases resulting from binding of 
electrophilic carcinogens or their metabolites with guanine which is the most 
prevalent target (Singer and Grunberger, 1983; Gamer, 1998). Alachlor and its 
metabolite CDEPA form covalent adducts with 2'-deoxyguanosine, 
2'-deoxythymidine and their 3'-monophosphates (Brown et al, 1988; Nesnow et al., 
1995). The adduct formation between alachlor or CDEPA with 2'-deoxyguanosine, 
2'-deoxythymidine involves the displacement of the chlorine atom of alachlor and 
CDEPA by nucleophiles under mildly basic conditions (Grabow et al., 1991). 
Alachlor-induced cytogenetic changes and formation of alachlor-DNA/alachlor-
protein adducts are the biomarkers of alachlor toxicity (Kligerman and Erexson, 
1999). High-performance liquid chromatography was performed to confirm the 
formation of alachlor adducts with DNA bases. Under identical conditions, alachlor 
treated guanine eluted at a retention time of ~7 min compared to pure guanine which 
eluted at ~5 min. The higher retention time of alachlor-treated guanine is suggestive 
of alachlor-guanine adduct formation. Thymine and alachlor-treated thymine showed 
identical retention time of-5.0 min, except for a kink at -5.3 min in alachlor-treated 
thymine, which may be probably due to small quantity of alachlor-thymine adduct or 
a non-covalent binding of alachlor with thymine. Alachlor-treated cytosine and 
cytosine eluted at identical retention time of -5.2 min. Similarly, no change in 
retention time was observed in adenine and alachlor-treated adenine. The above 
findings indicate that under our experimental conditions alachlor form adduct mainly 
with guanine and to some extent with thymine. 
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Native double stranded DNA (B-conformation) per se is non immunogenic 
(Isenberg et al, 1994; Habib et al., 2005), whereas upon modification with 
carcinogens, drugs, hormones, free radicals etc. DNA undergoes structural 
perturbations which lead to generation of new form recognized as foreign capable of 
eliciting immune response. In contrast to native mammalian DNA (B-form), bacterial 
DNA is a stronger immunogen (Gilkeson et al, 1989; Gilkeson et al, 1991; Krieg, 
2002). The immunogenicity of prokaryotic DNA has been attributed to the presence 
of nucleotide hexamers containing unmethylated CpG motifs tending to promote Thi-
like response (secretion of Thj cytokines such as IFN-y, TNF-a and IL-12). In 
contrast, CpG dinucleotides in mammalian DNAs are extensively methylated on 
cytosines and hence immunologically inert (Lundberg et al, 2003). The role of 
unmethylated CpG dinucleotide sequence in the immunogenicity of plasmid DNA is 
well recognized (Krieg et al, 1995). Immunization with single stranded DNA can 
elicit a limited antibody response, whereas dsRNA, RNA-DNA hybrids, DNA 
modified with drugs (Desai et al, 1993), hormones (Moinuddin and Ali, 1994) and 
free radicals (Alam et al, 1993; Hasan et al, 1995; Arjumand et al, 1995, 1997; 
Theofilopoulos, 1995; Dixit et al, 2005; Habib et al, 2005; Khan et al, 2006) are 
effective immunogens. 
Carcinogens form DNA adducts in vivo (Beland and Poirier, 1989), The potency 
of an adduct depends upon its sequence context, its metabolism and its ability or 
failure to be repaired (Weston and Poirier, 1994; Gamer, 1998). Antibodies elicited 
against DNA adducts have been used to quantify and localize xenobiotic-induced 
DNA damage and level of DNA adducts in humans (Lang et al, 1978; Santella et al, 
1990; Poirier and Weston, 1991). Immunogenicity of plasmid DNA and 
alachlor(i50fiM)-modified plasmid DNA was determined by induction of antibodies in 
experimental animals. Plasmid DNA itself was found to be a weak immunogen. The 
alachlor(i50)iM)-modified plasmid DNA proved to be a potent immunogen inducing 
high-titre antibodies (> 1.12800). Moreover, alachlor(3oonM)-modified plasmid DNA 
showed poor antibody induction and hence a weak immunogen. The immunogen 
specificity of anti-alachlor(i50nM)-modified plasmid DNA IgG was ascertained by 
competitive inhibition assay. A maximum of 74% inhibition was observed with 
alachlor(i50MM)-modified plasmid DNA used as antibody competitor.The concentration 
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of immunogen required for 50% inhibition of IgG binding to immunogen was 
9.2 p-g/ml. Inhibition ELISA of anti-alachlor(i50nM)-modified plasmid DNA IgG with 
plasmid DNA showed only 25% inhibition in antibody binding. The data suggests that 
modification of plasmid DNA by alachlor have generated immunogenic epitopes 
which triggered antibody response. Gel-shift assay was performed in order to confirm 
immunogen-antibody interaction. The retarded mobility due to the formation of 
specific immunogen-antibody complex reiterates the antibody specificity. 
Anti-alachlor(i50nM)-modified plasmid DNA IgG exhibited heterogeneity as 
demonstrated by binding with an array of antigens used as inhibitors. Calf thymus 
DNA and 400 bp calf thymus DNA showed moderate reactivity with anti-
alachlor(iJ0nM)-modified plasmid DNA IgG, whereas their alach!or(i5o^M)-modified 
analogs exhibited higher recognition of anti-alachlor(i50(iM)-modified plasmid DNA 
IgG. Human lymphocyte DNA modified by 150 jiM alachlor showed higher degree of 
cross-reactivity towards anti-alachlor(l5o^M)-modified plasmid DNA IgG compared to 
its untreated form. 
When the nitrogenous bases and their ROS- and 150 |j.M alachlor-modified 
conformers were used as inhibitors of anti-alachlor(i5o^M)-modified plasmid DNA 
IgG, it was observed that alachlor-modified bases were effective inhibitors compared 
to ROS-modified bases and unmodified bases. Among the alachlor-modified bases, 
alachlor-modified guanine showed higher inhibition of 45% followed by alachlor-
modified thymine (36% inhibition). Inhibition of anti-alachlor(i50nM)-modified 
plasmid DNA IgG binding by alachlor-modified guanine shows the significant 
contribution of alachlor-guanine adduct in presenting epitope for antibody induction. 
The binding of anti-alachlor(i50nM)-modified plasmid DNA IgG with an array of 
nucleic acid antigens indicate epitope sharing. Our data is in consonance with earlier 
reports on cross-reactivity (although limited) of anti-carcinogen-DNA adduct 
antibodies with unmodified DNA, unmodified nucleotides or carcinogen (Santella 
et ai, 1985), but other adducts of same carcinogen or adducts of chemically related 
carcinogen are better recognized by anti-carcinogen-adduct antibodies (Poirier, 1991). 
For instance, antibodies raised against benz(o)pyrene-DNA adduct cross-react with 
other aromatic hydrocarbons such as chrysene and benz(a)anthracene due to identical 
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chemical structure, thus having a broad spectrum of antibody recognition (Weston ef 
al, 1988). 
Many carcinogens cause DNA damage through adduct formation in target and 
non-target tissues. Covalent modifications of DNA by endogenous and exogenous 
electrophiles play a key role in carcinogenesis (Lin et al., 2002). The formation of 
DNA adduct in various human tissues have been studied as biomarkers of exposure to 
potential carcinogens (Bratsh, 1996; Hemminki, 1997; Poirier, 1997; Povey, 2000). 
DNA-adduct formation and single strand breaks are the initial events in 
carcinogenesis. In this context alachlor is a "likely" carcinogen. Earlier studies have 
shown that carcinogenicity of alachlor involve its bioactivation to a DNA-reactive 
metabolite 3,5-diethylbenzoquinone-4-imine [DEBQI], an electrophile capable of 
reacting with cellular macromolecules (Feng eial., 1990) 
The alachlor used in this study is a probable human carcinogen, capable of 
forming DNA-adduct and produces single strand breaks via free radical generation. In 
view of the potential carcinogenic nature of alachlor-DNA adduct it was thought to 
use this adduct as an antigen for the detection of antibodies in some types of cancer. 
With this above background in mind, sera of breast, lung and thyroid cancer were 
subjected to binding studies with plasmid DNA and alachlor(i50(iM)-modified plasmid 
DNA. We analyzed 40 sera each of breast & lung cancer and 30 sera of thyroid 
cancer. 
The binding specificity of IgG purified from sera of breast cancer patients were 
analyzed by competition ELISA using plasmid DNA and alachlor(i50nM)-modified 
plasmid DNA as competitors. Plasmid DNA showed inhibition in the range of 
20-31%, whereas with alachlor(i50nM)-modified plasmid DNA the inhibition was 
between 35-55%. The binding specificity of IgG purified from lung cancer sera were 
also evaluated by inhibition ELISA. The inhibition in antibody reactivity using 
alachlor(i50tiM)-modified plasmid DNA as inhibitor was in the range of 37-48% 
compared to plasmid DNA. Purified IgG from sera of thyroid cancer patients showed 
higher recognition towards alachlor(!50(iM)-modified plasmid DNA compared to 
plasmid DNA. DNA adducts characterized in experimental studies may have similar 
structure in human DNA arising from occupational and environmental exposures 
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(Gamer, 1998). In our studies the alachlor-DNA adduct used as an antigen showed 
appreciable recognition to antibodies from breast, thyroid and lung cancer. 
Conclusions: 
'^ Alachlor modification of plasmid DNA produced hyperchromicity, strand breaks, 
disruption of hydrogen bonds and helix destabilization. 
^ Alachlor forms adduct with DNA bases more specifically with guanine and to 
some extent with thymine. 
^ Binding of alachlor to plasmid DNA appears to be sequence specific as revealed 
by restriction enzyme assay. 
•^ Alachlor(i5o^M)-modified plasmid DNA was highly immunogenic in experimental 
animals compared to plasmid DNA. 
'^' Anti-alachlor(i50piM)-modified plasmid DNA IgG are polyspecific, showing cross-
reactivity to various nucleic acid antigens. 
"^ AIachIor(i50nM)-modified plasmid DNA presents better epitope for serum 
antibodies (or purified IgG) in cancer of breast, lung and thyroid. 
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